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Abstract 
The development of human placenta is a highly dynamic and tightly regulated process 
that involves proliferation, differentiation and apoptosis of specialized epithelial cells, the 
trophoblasts. Cytotrophoblasts (CTs) are able to proliferate and to differentiate into the 
non-proliferative multinucleated syncytiotrophoblast (ST) or develop an invasive 
phenotype, forming the extravillous trophoblasts, which remodel the uterine tissues and 
blood vessels. The syncytiotrophoblast is in direct contact with the maternal blood and is 
responsible for the mother-foetus gas and nutrient exchange and for the placental 
endocrine function. Anomalies during trophoblast proliferation, differentiation and 
apoptosis are related to pregnancy-associated complications, such as preeclampsia, 
intrauterine growth restriction or spontaneous miscarriages.  
In the last years, the relevance of the endocannabinoid system (ECS) in different 
physiological and pathological processes has been recognized. It is constituted by the 
cannabinoid receptors (CB1 and CB2), their endogenous ligands (endocannabinoids-
eCBs) and the biosynthetic and degradation enzymes of the endocannabinoids. The two 
major endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). They 
participate in neuroprotection, apoptosis, nociception and reproductive events. In fact, the 
endocannabinoid signalling is critical for fertility, implantation and decidualization. 
However, its importance during placental development remains unclear, though CB 
receptors and AEA metabolic enzymes have already been identified in this organ. In this 
way, one of the major aims of this work was to search for the presence of other key 
members of ECS, namely 2-AG metabolic enzymes (DAGL-α, MAGL) and the transient 
receptor potential vanniloid 1 (TRPV1), an AEA target, in primary human cytotrophoblasts 
syncytiotrophoblasts and in the cytotrophoblast cell model BeWo. It was demonstrated 
that these proteins are expressed in these cells. Then, the role of endocannabinoids in 
cytotrophoblast proliferation, differentiation and apoptosis and the underlying signalling 
pathways were investigated. AEA and 2-AG induced apoptosis and oxidative stress in 
BeWo cells, through a CB receptor-dependent mechanism. TRPV1 activation by AEA or 
its agonist capsaicin (CPS) also triggered apoptosis in human CTs. In addition, 2-AG 
impaired the biochemical and morphological differentiation of CTs into STs by the 
activation of CB receptors and these effects may be related to the 2-AG-induced decrease 
in cyclic AMP (cAMP) levels and protein kinase A (PKA) PKA phosphorylation. CPS also 
inhibited CT biochemical differentiation through a TRPV1-dependent mechanism, showing 
the importance of this receptor in cytotrophoblast differentiation. No significant AEA 
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effects were observed in this process. Collectively, these results contribute to the 
understanding of the eCBs function during cytotrophoblast cells turnover, namely in 
apoptosis and differentiation. In addition, the reported evidences suggest that these 
molecules are new regulators of these cellular events, pointing to a role for ECS and 
TRPV1 in placental development, and indicate that an abnormal endocannabinoid/ 
endovanniloid signalling may participate in mechanisms responsible for gestational 
diseases, such as preeclampsia or spontaneous abortion. 
  
  
 
Keywords: apoptosis; cytotrophoblast; endocannabinoid system; placenta; 
syncytialization; TRPV1 
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Resumo 
O desenvolvimento da placenta humana é um processo altamente dinâmico e 
extremamente regulado que envolve a proliferação, diferenciação e apoptose de células 
epiteliais especializadas, os trofoblastos. Os citotrofoblastos são capazes de proliferar e 
se diferenciar no sinciciotrofoblasto, camada multinucleada desprovida de capacidade 
proliferativa, ou de desenvolver um fenótipo invasivo, originando os trophoblastos 
extravilositários, que remodelam os tecidos uterinos e os vasos sanguíneos. O 
sincíciotrofoblasto está em contacto directo com o sangue materno e é responsável pelas 
trocas materno-fetais de gases e nutrientes e pela função endócrina placentária. 
Alterações na proliferação, diferenciação e apoptose dos trofoblastos estão relacionadas 
com complicações associadas à gravidez, tais como a pré-eclâmpsia, o atraso de 
crescimento intrauterino ou o aborto espontâneo. 
Nos últimos anos, a relevância do sistema endocanabinóide (ECS) tem sido 
reconhecida em diferentes processos fisiológicos e patológicos. O sistema é constituído 
pelos receptores canabinóides (CB1 e CB2), pelos seus ligandos endógenos 
(endocanabinóides-eCBs) e pelas enzimas de biossíntese e de degradação dos 
endocanabinóides. Os dois principais eCBs são a anandamida (AEA) e o 2-
araquidonoilglicerol (2-AG). Estas moléculas participam na neuroproteção, apoptose, 
nocicepção e em eventos reprodutivos. De facto, a sinalização endocanabinóide é crítica 
para a fertilidade, implantação e decidualização. No entanto, a sua importância durante o 
desenvolvimento placentário está ainda por elucidar, embora os receptores canabinóides 
e as enzimas metabólicas da AEA já tenham sido identificados neste órgão. Deste modo, 
um dos principais objetivos deste trabalho foi pesquisar a presença de outros membros-
chave do ECS, nomeadamente, as enzimas metabólicas do 2-AG (DAGL-α, MAGL) e o 
receptor de potencial transitório vanilóide do tipo 1 (TRPV1), um alvo da AEA, em 
culturas primárias de citotrofoblastos (CTs), sinciciotrofoblastos (STs) e no modelo celular 
de citotrofoblastos BeWo. Foi concluído que estas proteínas são expressas nestas 
células. Posteriormente, o papel dos endocanabinóides na proliferação, diferenciação e 
apoptose dos citotrofoblastos e as vias de sinalização subjacentes foram investigados. A 
AEA e o 2-AG induzem apoptose e stress oxidativo/nitrativo nas células BeWo, por um 
mecanismo dependente dos receptores canabinóides. A activação do TRPV1 pela AEA 
ou pelo seu agonista capsaicina (CPS) também induziu apoptose nos CTs. Além disso, o 
2-AG inibe a diferenciação morfológica e bioquímica dos CTs em STs, através da 
activação dos receptores canabinóides e é sugerido que estes efeitos podem estar 
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relacionados com a diminuição dos níveis de AMP cíclico e da fosforilação da proteína 
cinase A (PKA) induzida pelo 2-AG. A CPS também inibiu a diferenciação bioquímica dos 
CTs, por um mecanismo dependente do TRPV1, demonstrando a importância deste 
receptor na diferenciação dos citotrofoblastos. A AEA não induziu efeitos significativos 
neste processo. De um modo geral, estes resultados contribuem para a compreensão da 
função dos eCBs durante a remodelação dos citotrofoblastos, nomeadamente na 
apoptose e na diferenciação. Além disso, as evidências reportadas sugerem que estas 
moléculas são novos reguladores destes eventos celulares, sugerindo um papel para o 
ECS e o TRPV1 no desenvolvimento placentário e indicando que uma sinalização 
endocanabinóide/endovanilóide alterada pode estar envolvida nos mecanismos 
responsáveis por doenças relacionadas com a gravidez, tais como a pré-eclampsia ou o 
aborto espontâneo. 
 
 
 
Palavras-passe: apoptose; citotrofoblastos; sistema endocanabinóide; placenta; 
sincicialização; TRPV1 
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1. Development and functions of human placenta 
A new human life begins with the fertilisation of an oocyte by a spermatozoa, giving 
rise to the first cell of the new being, the zygote. Then, the zygote goes through 
successive mitosis originating the morula, which undergoes compaction forming the 
blastocyst. The blastocyst has an outer epithelial cell layer, the trophectoderm, which will 
form the placenta and extra-embryonic tissues; and an inner cell mass (ICM), which will 
give rise to the embryo. The blastocyst implantation occurs after 5-7 days of fertilization. 
For a successful implantation, it is required that the endometrium becomes receptive to 
the blastocyst, after differentiation of endometrial stromal cells (ESCs) into decidual cells. 
In humans, the decidualization occurs every menstrual cycle, in the late secretory phase, 
to prepare the endometrium for the implantation. If fertilisation does not occur, decidua is 
expelled during the menstruation and the endometrium is regenerated. If fertilisation 
occurs, the decidua is maintained and the endometrium undergoes further changes that 
include vascular and glandular remodelling and the appearance of the uterine immune cell 
populations.  
The formation of placenta begins with the differentiation of the trophectoderm in 
different trophoblasts, the specialized epithelial cells of placenta. In the prelacunar stage, 
trophoblast cells proliferate and differentiate into the multinucleated syncytiotrophoblast 
(ST), which has an invasive phenotype in this stage, allowing the blastocyst penetration 
into the decidua. The remaining mononuclear cells are the cytotrophoblasts (CT) and act 
as stem cells, permitting the growing of ST layer. In the lacunar stage, fluid-filled spaces 
appear in the syncytiotrophoblast and merge, forming the lacunae. The lacunae are 
surrounded by the trabeculae (a ST mass), which will be important for the villous trees 
formation. At this stage, CTs invade the trabeculae and reach the maternal tissues, giving 
rise to the extravillous trophoblasts (EVTs). In the villous stage, the trabeculae begin to 
branch and contain a core filled with CT, forming the primary villi. Then, the 
extraembryonic mesodermal cells go along with the CTs and invade the trabeculae, 
though not reaching the maternal side, giving rise to the secondary villi. The mesodermal 
cells differentiate into haematopoietic cells and, then, blood vessels independent on 
embryo vascular system emerge, originating the tertiary villi [1]. 
At microscopic level, placenta is then constituted by villous trees that keep emerging 
from the continuous branching of trabeculae. Some of them contact with the basal plate 
(region facing the endometrium) and contain the trophoblastic cell columns (anchoring 
villi), while other end freely in the intervillous space (floating villi) [1]. This placental 
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microarquitecture allows an intimate contact between mother and foetus, since the 
maternal blood is in direct contact with trophoblast foetal cells, due to the deep invasion of 
maternal tissues. This type of placentation is called haemochorial [2]. 
Macroscopically, the human term placenta is a discoid organ with about 22 cm of 
diameter but there is a considerable interindividual variability of its anatomy. The basal 
plate is divided in lobes/cotyledons, which contain the chorionic villi that arise from the 
foetal side of placenta (the chorionic plate) and are irrigated by foetal blood vessels [1].  
The placental development is a dynamic and highly regulated process and anomalies 
in this gestational event will impair the important functions of human placenta, such as gas 
and nutrient exchanges and embryo protection [3], compromising the success of 
pregnancy outcome. The main functions of this organ are summarized in Figure 1.  
 
             
Figure 1. Main functions of human placenta. 
hCG- human chorionic gonadotropin; hPL- human placental lactogen; PP13- placental protein 13. 
 
 
1.1 The trophoblast 
In placental environment, there are several cell types that contribute to placental 
structure and function, including trophoblasts, decidual cells, mesenchymal cells, 
Hofbauer cells (placental macrophages) and endothelial cells [1]. The trophoblasts are the 
main placental cells. In human placenta, there are four types of trophoblasts: 
cytotrophoblast, syncytiotrophoblast, extravillous trophoblasts, and giant trophoblast cells. 
They have different morphologies, properties and functions, which turns the placenta into 
a unique organ. Figure 2 represents the mother-foetal interface, with the structure of 
human chorionic villi and the trophoblast cell types. 
 
Nutrient supply: aminoacids, glucose and lipids, H2O, vitamins, inorganic ions 
Gas exchanges 
Removal of waste products
Metabolism 
Protection: immunoprotection, barrier against xenobiotics
Endocrine funtion: hCG, oestrogens, progesterone, hPL, leptin, PP13, 
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Figure 2. Representation of the mother-foetal interface.  
CTs are able to proliferate and fuse to originate a multinucleated layer, the ST. In the anchoring villi, CT form a 
cytotrophoblast cell column. Then, CTs differentiate into invasive trophoblasts, which will remodel the maternal 
decidua (iEVTs) and blood vessels (enEVTs), enlarging the spiral arteries caliber and consequently 
diminishing the resistance to the blood flow that irrigates the foetus. In the myometrium, to limit their invasion 
into maternal tissues, iEVTs fuse, giving rise to the multinucleated GCs. CT- cytotrophoblast; DC-decidual cell; 
EC- endothelial cell; enEVT- endovascular extravillous trophoblast; GC- giant trophoblast cell; iEVT- interstitial 
extravillous trophoblast; MC- myometrial cell; ST-syncytiotrophoblast. 
 
 
The villous cytotrophoblasts are the first trophoblast cell type to differentiate from the 
trophectoderm. They are mononuclear cells that proliferate, differentiate into other 
trophoblast cell types and die by apoptosis. Their proliferation is essential for the placental 
development and maintenance. CT proliferation is regulated by oxygen and growth factors 
and is higher in the first trimester, when the oxygen tension is lower, decreasing in the 
following trimesters [4]. 
Cytotrophoblast differentiation occurs by two pathways: the villous and the extravillous 
pathways (Figure 3). In the villous pathway, CTs proliferate, aggregate, fuse and undergo 
biochemical differentiation to originate the syncytiotrophoblast; this process is called 
syncytialization. In the extravillous pathway, CTs proliferate and acquire invasion 
properties, which allow the invasion of uterine arteries (endovascular trophoblasts; 
enEVTs) and endometrium (interstitial trophoblasts; iEVTs) [3, 5, 6].  
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Figure 3. Schematic representation of the differentiation pathways of human cytotrophoblasts.   
 
 
The extravillous trophoblasts are mononucleated cells with invasive capacity that 
remodel the uterine tissues and maternal spiral arteries. The iEVTs invade the decidua 
and the inner third of the myometrium. There, they aggregate and fuse, forming the 
placental bed giant trophoblast cells (GCs). These cells are multinucleated cells that are 
not able to migrate and invade and their formation is considered a regulatory mechanism 
of trophoblast invasion since prevents a deeper penetration into the uterine wall [7]. iEVTs 
induce a loss of vascular smooth muscle cells (VSMC) of spiral arteries and enEVTs 
invade the spiral artery, replace endothelial cells and form plugs in the spiral artery, 
creating a hypoxic environment in the first trimester. EVTs induce caspase-dependent 
apoptosis in VSMC via TNF-related apoptosis-inducing ligand (TRAIL) and in endothelial 
cells via TRAIL and FasL. These changes aim to increase the blood vessel calibre and, 
concomitantly, diminish the resistance to the blood flow, facilitating the gas and nutrient 
exchange [8]. The spiral arteries remodelling is a key event during placental development 
since an insufficient invasion is associated with gestational diseases like preeclampsia [9].  
The trophoblast invasion involves restructuration of extracellular matrix and so, EVTs 
show a distinct profile of adhesion molecules (e. g. increased expression of some 
integrins or VE-cadherin and lower expression of E-cadherin). Furthermore, they express 
proteases like matrix metalloproteinases (MMPs) and urokinase plasminogen activator 
(uPA) that are able to degrade the extracellular matrix. On the other hand, they also 
express protease inhibitors, tissue inhibitors of metalloproteinase (TIMPs) and 
plasminogen activator inhibitors, which regulate EVTs invasion into maternal tissues. 
Several growth factors and other proteins have a stimulatory (e. g. leptin, activin A, 
epidermal growth factor EGF) or inhibitory (transforming growth factor TGF-β, inhibin A) 
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effect on EVTs invasion. Besides trophoblasts, other placental cells like decidual cells, 
uterine NK cells and activated macrophages also produce some of these factors, 
participating in the control of EVTs invasion. Moreover, EVTs express a distinct human 
leucocyte antigens (HLA) profile, which contributes to the immunotolerance at the 
maternal-foetus interface [9]. 
Besides enEVTs and iEVTs, recent evidences indicate that there is another EVT 
population, the endoglandular trophoblasts, suggesting that uterine glands undergo 
remodelling, which aims the opening of glands lumen to the intervillous space, providing 
histiotrophic nutrition to the embryo before the uteroplacental circulation during the early 
placental development [10].  
 
 
 
1.1.1 Syncytialization 
The cytotrophoblast differentiation into syncytiotrophoblasts is an event that begins a 
few days after implantation and continues till the end of pregnancy. The mononuclear CTs 
undergo morphological and biochemical differentiation to form a non-proliferative 
multinucleated cell layer that directly contacts with the maternal blood, the 
syncytiotrophoblast, which is the only barrier that separates mother and foetal blood. This 
syncytial layer is maintained by continuous fusion of the underlying cytotrophoblast cells 
and is involved in the foetal nourishment, protection and protein biosynthesis.  
The mononucleated CTs aggregate and fuse into the ST multinucleated layer. In this 
process, there is a rearrangement of the cytoskeleton with α-fodrin fragmentation and 
actin reorganization and decrease of E-cadherin expression [11, 12]. These changes are 
enhanced by the activation of the transcription factor glial cells missing 1 (GCM-1) [13, 
14]. GCM-1 regulates the transcription of the human endogenous retroviral genes 
(HERVs), HERV-W and HERV-FRD, which codify the fusogenic proteins syncytin-1 and 2, 
respectively [13, 15-18]. The biochemical or functional differentiation is responsible for the 
ST expression of proteins involved in transport, metabolism and production of several 
hormones and enzymes, which are essential for a successful pregnancy outcome, such 
as human chorionic gonadotropin (hCG), human placental lactogen (hPL), leptin, 
aromatase and placental alkaline phosphatase (pALP) [6, 19]. 
Cytotrophoblast fusion and differentiation is regulated by several signalling pathways. 
Some of the factors that modulate the syncytialization are summarized in Table 1.  
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Table 1. Factors that modulate the syncytialization.  
Factor Specification Effect in syncytialization Ref. 
Connexin-43 gap-junction protein ↑ Bd/Md* [20, 21] 
EGF growth factor ↑ Bd/Md [22, 23] 
CSF growth factor ↑ Bd/Md [24] 
GM-CSF growth factor ↑ Bd/Md [24] 
IGF-1 growth factor ↑ Bd [25] 
TNF-α cytokine ↓ Bd/Md [26] 
TGF-α growth factor ↑ Bd/Md [27] 
TGF-β growth factor ↓ Bd [28, 29] 
Oestradiol hormone ↑ Bd/Md [30] 
hCG hormone ↑ Bd/Md [31, 32] 
Adiponectin adipocytokine ↑ Bd/Md [33] 
Activin growth factor ↑ Bd [29] 
LIF cytokine ↑or↓ Bd; ↑Md* [34-37] 
Caspase-8 protease ? [38, 39] 
Caspase-14 protease ↓Bd/Md* [40, 41] 
GCM-1 transcription factor ↑ Bd/Md [13, 14] 
Syncytin-1 endogenous retroviral envelope protein ↑ Bd/Md [15, 18] 
Syncytin-2 endogenous retroviral envelope protein ↑ Bd/Md [16] 
Cadherin-11 cell adhesion protein ↑ Bd*/Md [42] 
PPAR-γ nuclear receptor ↑ Bd/Md [43, 44] 
RXR-α nuclear receptor ↑ Bd [45, 46] 
CD98 membrane protein; amio acid transporter  ↑ Md* [47, 48] 
MFSD2a syncytin-2 receptor ↑ Md* [49] 
cAMP second messenger ↑ Bd/Md [50, 51] 
p38 kinase ↑ Bd/Md [52] 
p42/p44 kinase ↑ Bd/Md [52] 
PKA kinase ↑ Bd/Md [50, 51] 
Src family kinases kinases ↑ or↓Bd/Md [53] 
Epac guanine nucleotide exchange factor ↑ Bd/Md [54, 55] 
Calponin 3 cytoplasmic protein ↓ Md* [56] 
Galectin-1 lectin ↑ Md* [57] 
Galectin-3 lectin ↑ Md* [47] 
RhoE Rho GTPase family protein ↑ Md* [58] 
Intermediate 
conductance Ca2+-activated 
K+ channels  
potassium ion channels ↓ Bd/Md [59] 
voltage-gated K+ channels potassium ion channels ↓ Bd [60] 
Stathmin microtubule regulatory protein ↑ Bd/Md* [61] 
Syndecan-1 membrane-bound proteoglycan ↑ Bd/Md* [62] 
Twist transcription factor ↑ Md* [63] 
ZO-1 (zona ocludens 1) membrane proteins ↑ Bd/Md [64] 
Hypoxia environment condition ↓ Bd/Md [65, 66] 
↑-stimulation, ↓-inhibition; ?- inconsistent; Bd-biochemical differentiation; Md- morphological differentiation; 
*data obtained with cytotrophoblast cell lines. 
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The signalling cascade cyclic AMP/ protein kinase A/cAMP response element binding 
protein (cAMP/PKA/CREB) is one of the major interveners in the ST formation. In fact, 
during this process, cAMP levels increase leading to phosphorylation of PKA and, 
consequently, of CREB, promoting CTs biochemical differentiation [50, 67-71]. In addition, 
cAMP has been related to CTs morphological differentiation, since it regulates the 
expression of GCM-1 and syncytin-1 and 2 [51, 72]. Besides the activation of PKA, 
increased cAMP levels may also induce CT fusion and differentiation by the activation of 
the exchange protein directly activated by cAMP (Epac) signalling pathway [54, 55, 73]. 
The phosphorylation of mitogen-activated protein kinases (MAPKs) p38 and 
extracellular signal-regulated kinase 1/2 (ERK 1/2) also triggers the cytotrophoblast 
differentiation [52]. In fact, p38 phosphorylation mediates EGF stimulation of 
syncytialization [23], whereas phosphorylation of both p38 and ERK 1/2 are involved in 
the biochemical differentiation induced by the inhibition of Src family kinase [74]. 
Moreover, p38 regulates the expression of peroxisome proliferator-activated receptor 
(PPAR-γ) [75], whose activation also triggers both fusion and biochemical differentiation of 
CTs, by stimulating the secretion of hCG, hPL and leptin and the transcription of GCM-1 
and syncytin-1 [43, 44, 46, 76].  
Some authors defend that the exposure of phosphatidylserine to the outer leaflet of 
plasma membrane and caspase 8 activation, are involved in CTs plasma membrane 
remodelling, contributing to their fusion [38, 77]. However, other evidences raised 
questions about the role of caspase-8 in this process and suggest that the activation of 
this protease is not required for syncytialization [39, 78].  
 
 
1.1.2 Apoptosis in trophoblast 
Besides proliferative and differentiation events, the apoptotic cell death of trophoblasts 
is another important cellular process for placental development, since it removes the 
quiescent cells without inducing an inflammatory reaction, allowing the proliferation and 
differentiation of new cells. However, the mechanisms involved in the regulation of 
trophoblast apoptosis still need to be clarified. It was reported that an abnormal 
expression of apoptotic proteins, such as Bax, Bcl-2 or FasL are associated with 
pathological conditions like preeclampsia, HELLP syndrome, IUGR and hyperglycaemia 
[79-84]. There are some controversies about the trophoblast phenotypes that undergo 
apoptosis. Huppertz et al. proposed that the CTs only present early stage apoptotic 
features, such as caspase-8 activation and phosphatidylserine exposure in the outer 
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leaflet of plasma membrane, features that lead to cell fusion. Moreover, they express high 
levels of the anti-apoptotic protein Bcl-2, which inhibits the progression of the apoptotic 
cascade. Later, after fusion into the ST, this cascade is reactivated and the aged and 
apoptotic syncytiotrophoblast nuclei are aggregated into protrusions of the apical 
membrane, forming the syncytial knots. Then, these structures are extruded and released 
into the maternal blood [85]. However, other authors reported that CTs are the main cells 
that undergo apoptosis and the apoptotic markers that apparently were localized in the ST 
were actually from apoptotic CTs, which were highly interdigitated into the ST [86]. Also, 
recent evidences suggest that apoptosis inhibition in ST is important because, once 
initiated, it would widespread throughout the entire syncytial layer, leading to placental 
dysfunction [87]. The EVTs also undergo apoptosis, though few information is known 
about this process. Nevertheless, it seems that decidual, endothelial and local immune 
cells may modulate EVTs apoptosis [85]. 
The proteins required to trigger the mitochondrial and death receptor pathways are 
expressed in CTs, STs and EVTs [88, 89]. In normal conditions, cytotrophoblasts do not 
undergo apoptosis after Fas activation [90, 91], probably because these cells express 
high levels of  X-linked inhibitor of apoptosis (XIAPs) and cellular FLICE-like inhibitory 
protein (c-FLIP) [88]. On the other hand, CT cells induce a Fas and TRAIL-mediated 
apoptosis in T cells and VSMC, respectively [92, 93].  
 
 
1.2 Placental hormones 
The placental hormones are important throughout pregnancy, since they play a role in 
pregnancy establishment and maintenance, foetal development and labour. The major 
source of placental hormones is the syncytiotrophoblast layer. The ST has the enzymatic 
machinery required for the biosynthesis of several hormones, which are not expressed in 
other trophoblast phenotypes.  
 
 
 
1.2.1 Human chorionic gonadotropin (hCG) 
The human chorionic gonadotropin (hCG) is one of the most important pregnancy-
related hormones. It is a glycoprotein that shares similarities with the hypophysary 
luteinizing hormone (LH). Besides the hCG hormone characteristic of pregnancy, there 
are other 4 variants of this protein, with similar amino acid sequences but produced by 
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different cells and with different functions: sulphate hCG, hyperglycosylated hCG, hCG 
free β-subunit and hyperglycosylated hCG free β-subunit. 
The pregnancy-produced hCG act on LH/hCG receptors and its main functions include 
stimulation of progesterone secretion by corpus luteum, angiogenesis of uterine 
vasculature, promotion of the CTs fusion and differentiation into ST, immunosuppression 
and prevention of myometrial contractions. hCG is detectable from day 8 after ovulation 
and its levels peak at 10th week of pregnancy, declining slowly till the end of the 
gestational period [94]. As it is almost exclusively produced during pregnancy (there are 
some cancerous cells that produce this hormone), the detection of this hormone in blood 
and urine is the most common biomarker used in pregnancy tests. 
The signalling pathways involved in hCG biosynthesis are already elucidated. The 
cAMP/PKA pathway stimulates hCG production [50, 71]. On the other hand, the activation 
of LH/hCG receptor also enhances adenylyl cyclase (AC) activity, increasing cAMP levels 
[95]. Moreover, Src kinases are also able to modulate hCG secretion [53] and, in the 
cytotrophoblast cell model BeWo cells, a crosstalk between cAMP/PKA and MAPKs p38 
and ERK1/2 pathways mediates the forskolin-induced increase in hCG levels, promoting 
CT differentiation [96].  
 
 
1.2.2 Progesterone 
Progesterone is a steroid essential for pregnancy maintenance. It is synthesised from 
cholesterol through a two-step reaction occurring in trophoblast mitochondria: cholesterol 
side-chain cleavage by cytochrome P450 (CYP450scc) converts maternal cholesterol into 
pregnenolone, which is metabolized to progesterone by 3-β-hydroxysteroid 
dehydrogenase (3-β-HSD) [97]. At the beginning of gestation, luteal corpus is the main 
producer of progesterone but from 6th week of gestation till the end of pregnancy, placenta 
becomes the main source of this steroid and progesterone serum levels increase till the 
end of gestation. Progesterone acts in several events throughout gestational period: 
stimulates decidualization and myometrial relaxation and quiescence, enhances the 
expression of profertility Th2 cytokines in decidual cells, blocks the oestrogens pro-
proliferative effect in the uterine cells, promotes embryo attachment, modulates hCG 
synthesis and represses MMPs activity, impairing trophoblast invasion. It acts by binding 
to two types of receptors: nuclear and membrane-bound progesterone receptors [98, 99].  
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1.2.3 Oestrogens 
Placental oestrogens are steroids that consist in four different hormones: oestrone, 
oestradiol, oestriol and oestretol. On the contrary to other steroidogenic organs, placenta 
is not able to convert pregnenolone and progesterone into androgens, since 17α-
hydroxylase/17, 20-lyase is absence in this organ. In this way, placenta uses circulating 
androgens that essentially come from foetal adrenal glands (but also from the mother), 
and the enzyme CYP450 aromatase expressed in the syncytiotrophoblast converts them 
into oestrogens [97]. Aromatase activity is modulated by cAMP levels [100]. Oestradiol 
promotes implantation, vasodilatation and increases uterine contractions in labour. 
However, oestradiol actions in the trophoblasts remain unclear. Moreover, oestradiol 
enhances syncytialization, induces leptin expression and may, indirectly, modulate EVTs 
function [98, 101].  
The oestriol is the most abundant oestrogen in the urine. It is considered a weak 
oestrogen, though it is important for increasing uteroplacental blood flow and is one of the 
hormones tested for screening foetal anomalies [97].  
 
 
1.2.4 Leptin and other adipokines 
Adipokines are adipocyte-derived signalling proteins that, in the last years, have 
emerged as important regulators of gestational events, namely in placental development. 
Leptin is the most well-known adipokine in pregnancy. Serum levels of leptin are 
increased in pregnant women, peaking in late 2nd and early 3rd trimester. The main source 
of leptin is the syncytiotrophoblast and leptin receptors are also expressed in this 
multinuclear layer. This hormone has pleotropic effects in pregnancy, such as in 
implantation, angiogenesis, embryo development, stimulation of hCG secretion, CT 
proliferation and induction of MMP-2 and MMP-9 synthesis and, consequently, EVTs 
invasion. Leptin triggers JAK/STAT, ERK1/2 and Phosphoinositide 3-kinase (PI3K) 
pathways [102]. Its expression is regulated by other pregnancy hormones like hCG, hPL, 
insulin, progesterone, oestrogens and by the second messenger cAMP. In fact, cAMP 
induces the expression of leptin, in a mechanism that also involves a crosstalk between 
PKA and ERK1/2 pathways [103]. Additionally, hCG enhances the production of leptin 
through a mechanism that involves an interplay between cAMP and p38 [104] and also by 
the Epac/cAMP pathway [105]. 
Adiponectin is another adipokine whose importance in placentation has been 
recognized. It exerts several tissue-specific effects, partially depending on the several 
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isoforms found in the circulation: trimmers, hexamers and high molecular weight 
multimers. Its serum levels are increased in early pregnancy and then decline in the 
second trimester [106]. Adiponectin diminishes the endocrine function of term 
syncytiotrophoblast, since it decreases hCG, progesterone and hPL secretion [107]. On 
the other hand, it enhances syncytialization in first trimester [33] and has antiproliferative 
effects on trophoblastic cell lines, BeWo and JEG-3 [108]. Moreover, adiponectin 
stimulates the migration and invasion of first trimester EVTs, through the upregulation of 
MMP-2 and -9 and downregulation of TIMP-2 [109].This cytokine also inhibits insulin 
signalling and insulin-stimulated amino acid transport [110] through the activation of 
PPAR-α and ceramide synthesis [111].  
Resistin serum levels are increased in the 3rd trimester of gestation. This adipokine is 
expressed in EVTs and increases MMP-2 whereas decreases TIMP-1 and -2, promoting 
cell invasion. Resistin also stimulates angiogenesis [106]. 
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2. The Endocannabinoid System 
The consume of Cannabis sativa either for medicinal or recreational purposes began a 
thousand years ago in central Asia. The medicinal properties of this plant were first 
explored in China, India, Egypt, Syria, Persia and Tibet, where it was used for the 
treatment of malaria, constipation, rheumatism, pain, absentmindedness, menstrual 
fatigue, sleep disorders [112-114]. However, the first cannabinoids were only identified in 
the 60’s: the Cannabidiol (CBD) [115] and the most psychoactive constituent of cannabis, 
∆9- tetrahydrocannabinol (THC) [116].   
After the identification of THC, an intense research about its mechanism of action 
began. The strong hydrophobicity of this molecule suggested that its actions resulted from 
non-specific interactions with cell membrane [117]. However, the synthesis of THC 
enantiomers and its synthetic analogues, as well as the discovery that THC was 
enantioselective indicated that THC effects were receptor-dependent. In 1988, the first 
cannabinoid receptor (CB1) was identified in rat brain by Devane et. al. [118] and in 1992, 
the first endogenous ligand of this receptor, the N-arachidonoylethanolamine or 
Anandamide (AEA), was discovered in porcine brain [119]. Then, in 1993, the second 
cannabinoid receptor CB2 was identified in human promyelocytic leukemia cells (HL-60 
cells) [120]. These discoveries and the identification of other endogenous ligands for CB1 
and CB2 contributed to unveil the existence of the Endocannabinoid System (ECS). 
Nowadays, the members that constitute this system are the cannabinoid receptors (CB1 
and CB2), their endogenous ligands (endocannabinoids – eCBs), the enzymes involved in 
synthesis and degradation of these ligands and the eCBs putative membranar transporter 
(EMT). In Figure 4, the members of ECS are represented, as well as their role in the 
system. 
In the last years, the ECS has been studied in several scientific fields and it has 
emerged as an important intervener in different physiological and pathophysiological 
mechanisms. Actually, drugs targeting the members of ECS have been explored as 
therapeutic alternatives for the treatment of pathological conditions such as pain, cancer, 
obesity, inflammation and neurodegenerative disorders [121]. The drugs that target ECS 
are divided in several families such as direct agonists or antagonists of CB receptors and 
inhibitors of eCBs biosynthesis, degradation or reuptake [122]. Cannabinoid agonists, like 
THC or the synthetic cannabinoid nabilone are legally used in some countries to treat 
nausea and emesis in cancer patients undergoing chemotherapy and to induce appetites 
in AIDS patients. These compounds have also proved efficacy in the management of 
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interferon and ribavirin-induced anorexia, nausea and weight loss in chronic hepatitis C 
patients. In Portugal, a spray containing THC and cannabidiol (CBD), Sativex®, is 
commercialized since 2012 for the treatment of spasticity in multiple sclerosis patients 
[123]. The selective antagonist of CB1 receptor, Rimonabant (Acomplia®) was a promisor 
anti-obesity drug and was commercialized in several countries. However, Acomplia® was 
discontinued due to its psychiatric side effects (anxiety and depression) [124].  
 
 
 
Figure 4. Biochemistry of the endocannabinoid system (ECS).   
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are synthetized from membrane precursors. AEA is 
synthesised by the enzymes N-acyltransacylase (NAT) and N-acylphosphatidoylethanolamine- Phospholipase 
D (NAPE-PLD), whereas the synthesis of 2-AG is catalysed by Phospholipase C (PLC) and Diacylglicerol 
lipase (DAGL). Both eCBs are released to the extracellular environment by diffusion or selective 
endocannabinoid membrane transporter (EMT), where they activate G.protein-coupled cannabinoid receptors 
(CBR). Then, they are rapidly internalized also by diffusion /EMT and are degraded. AEA is mainly hydrolysed 
by fatty acid amid hydrolase (FAAH), releasing ethanolamine (EA) and arachidonic acid (AA) or is oxidized by 
Cyclooxygenase 2 (COX-2), to prostaglandin-ethanolamides (PG-EA). 2-AG is converted to glycerol and AA 
mainly by Monoacylglycerol lipase (MAGL) or is oxidized by COX-2 to prostaglandin-glyceryl esters (PG-GE). 
In addition, AEA is capable of activating the cation channel transient receptor potential vanilloid 1 (TRPV1) 
receptor in the intracellular side and both AEA and 2-AG are able to bind to the nuclear receptors peroxisome 
proliferator-activated receptor (PPAR), modulating the transcription of their target genes.  
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2.1 Endocannabinoids 
By definition, endocannabinoids are endogenous lipid molecules that are capable of 
binding to and functionally activate cannabinoid receptors, exerting similar cellular effects 
to the most psychoactive constituent of Cannabis sativa, the THC.  
As abovementioned, the first eCB N-arachidonoylethanolamide (Anandamide, AEA) 
was identified in 1992 in porcine brain [119]. In the following years, other eCBs have also 
been identified:  2-arachidonoylglycerol (2-AG) [125, 126], 2-arachidonoyl glyceryl ether 
(2-AGE) [127], O-arachidonoylethanolamine (virodhamine) [128], N-
arachidonoyldopamine (NADA) [129], N-arachidonoylglycine (NAGly) [130] and Oleamide 
[131]. Chemically, these molecules are amides, esters or ethers of long-chain 
polyunsaturated fatty acids and are structurally different from THC but share critical 
pharmacophores [132, 133]. They are synthesised in cytoplasm through multiple 
biosynthetic pathways and released into the extracellular environment, where they bind 
and activate CB receptors. After exerting their action, eCBs are internalized and degraded 
[134]. The molecular structure of THC and eCBs are represented in Figure 5.  
All eCBs have different affinities for cannabinoid receptors and exhibit differences in 
their pharmacological profile comparing with THC and synthetic cannabinoids. Some 
eCBs are able to activate other receptors like the Transient Receptor Potential Vanilloid 
Type-1 (TRPV1) and PPAR-α and γ [135].  
Anandamide and 2-AG are the best characterized members of the main eCBs families, 
the N-acylethanolamides (NAE) and monoacylglycerols (MAG), respectively. Since the 
pharmacology and metabolism of these compounds are the most well-known, they are 
considered as ‘major’ endocannabinoids.  
Besides eCBs, there are other endogenous molecules, “endocannabinoid-like”, which 
are able to modulate the endocannabinoid signalling, although they are devoid of activity 
on CB receptors. These molecules are denominated eCB-like compounds and share the 
hydrolysing enzymes with the eCBs, exacerbating their effects by an ‘entourage’ effect, 
due to the competitive inhibition of these enzymes [136].   
 
 
2.1.1 Anandamide (AEA) 
N-arachidonoylethanolamine or Anandamide is the best-characterized eCB. The name 
Anandamide comes from the Sanskrit word ananda, which means ‘internal bliss’ [137]. As 
the other NAEs, this lipid is an endogenous eicosanoid derivative, which is synthesized 
from phospholipids of cell membrane and arachidonic acid, linked by an amide bound. Its 
17 
 
main biosynthetic enzyme is N-acyl-phosphatidylethanolamine (NAPE-PLD), whereas the 
main hydrolysing enzyme is Fatty Acid Amide Hydrolase (FAAH) [134].  
 
 
 
Figure 5. Chemical structures of the psychoactive phytocannabinoid THC and of the endogenous 
cannabinoids. 
 
 
It is known that AEA is very important in numerous physiologic processes like 
modulation of different stages of reproduction [138-141], nociception [142, 143], muscle 
relaxation [144, 145], inflammation [146, 147], stimulation of appetite [148, 149], cell 
differentiation [150-152] and apoptosis  [138, 153-155]. For a long time, researchers 
thought that AEA and other eCBs were synthetized ‘on demand’. However, recent data 
∆9-Tetrahydrocanabinol (THC) Anandamide (AEA)
2-Arachidonoylglicerol (2-AG) 2-Arachidonoylglicerol Ether (2-AGE)
Virodhamine N-arachidonoyldopamine (NADA)
N-arachidonoylglycine (NAGly) Oleamide (ODA)
18 
 
demonstrated that AEA can be stored inside the cell in adiposomes [156]. Moreover, AEA 
can interact with soluble carrier proteins facilitating its trafficking [157, 158].  
Anandamide acts as partial agonist of both cannabinoid receptors, which is unusual for 
an endogenous ligand. Like THC, AEA has lower efficacy and affinity for CB2 than for 
CB1 [159]. Besides cannabinoid receptors, AEA can also activate TRPV1, a non-selective 
cation channel [160] and so, this eCB is also considered an endovanilloid. This receptor 
can also be responsible for some AEA cellular effects, like vasodilation and apoptosis 
[161]. AEA can also activate the nuclear receptors PPAR-α [162] and PPAR-γ [163]. 
Interestingly, AEA is able to downregulate the levels of the other major eCB, 2-AG, 
through activation of TRPV1 in postsynaptic neurons, resulting in an inhibition of 2-AG 
synthesis by Diacylglycerol Lipase α (DAGL-α) [164]. 
In this way, AEA is capable of acting inside the cell through the activation of TRPV1 
and PPARs and exerting an autocrine and/or paracrine effect on CB receptors when it is 
released from the cell [165]. AEA in the extracellular fluid can reach different targets with 
the help of protein carriers like serum albumin and lipid-binding proteins, such as 
lipocalins [166], acting as an endocrine messenger [165].  
 
 
2.1.2 2-arachidonoylglycerol (2-AG) 
2-arachidonoylglycerol was an already known endogenous metabolite when, in 1995, 
Mechoulam et al. identified it in canine gut and described its intrinsic activity on CB1 and 
CB2 [125]. Sugiura et al. also found that this eCB binds to the cannabinoid receptors in rat 
brain synaptosomes [126]. There are emergent evidences that 2-AG is an important 
messenger in multiple physiological processes such as neuroprotection [167, 168], 
inflammation [169-171], nociception [172, 173], reproductive events [174, 175], cell 
differentiation [176, 177]  and apoptosis [175, 178]. Similarly to AEA, 2-AG is synthesised 
in the cytoplasm through different pathways and the most relevant is the one involving the 
enzyme diacylglycerol lipase (DAGL). The major 2-AG hydrolysing enzyme is 
monoacylglycerol lipase (MAGL) [134]. 
2-AG binds to CB1 and CB2 receptors with higher efficacy than AEA but the affinity for 
CB2 is slightly lower than for CB1 [159]. Unlike AEA, 2-AG acts as full agonist in various 
systems and seems that its structure is strictly recognized by the cannabinoid receptors, 
which leads some authors to conclude that 2-AG is the true natural ligand for the CB 
receptors [179]. It has been referred that the concentration of 2-AG in the brain is between 
170 [180] to 800 [126] times higher than AEA. Also, in mouse uterus and in rat decidual 
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cells, 2-AG levels are, respectively, 200- and 150-fold higher than those of AEA [174, 
175].  In contrast with AEA, 2-AG seemed to be a very weak activator of TRPV1 [160], 
though recent evidences support that this eCB is also a ligand of this receptor [181, 182]. 
2-arachidonoylglycerol, as AEA, activates PPAR-γ [163]. 
 
 
2.2 Receptors for the endocannabinoids 
Cannabinoid receptors, CB1 and CB2, are members of the superfamily of G protein-
coupled receptors (GPCR), which have a seven-domain transmembrane structure. Their 
ligands bind to the extracellular domain, activating different cellular pathways. Initially, it 
was thought that THC effects resulted from its interaction with cellular membranes, which 
would stimulate or inhibit membrane-associated enzymes and alter the physical state of 
ion channels [117, 183]. However, the finding that THC induced an inhibition of AC and a 
decrease in the levels of cAMP in neuroblastoma cells constituted the first evidence of the 
existence of cannabinoid receptors [184, 185]. These inhibitory effects were blocked by 
pertussis toxin (PTX), suggesting the involvement of Gi/0 proteins [186]. In 1988, a study 
using a radiolabelled and enantiomerically pure analogue of THC allowed the identification 
of specific binding sites in the brain, the CB1 receptors [118]. In 1990, these receptors 
were cloned from rat brain [187]. Later, in 1993, the discovery of CB2 demonstrated that it 
only shares 44% of amino acid sequence homology with CB1 [120]. While CB1 receptor is 
highly conserved across the human, rat and mouse species, CB2 protein structure is 
divergent, which may have implications for future pharmacological studies involving CB2 
[188]. Initially, it was thought that CB1 was only localized in brain and that CB2 was 
restricted to immune system, however, their distribution is more ubiquitous. Besides brain, 
CB1 is peripherally expressed in several organs, including spleen, tonsils, bladder, small 
intestine, sympathetic nerve terminals, smooth muscle cells and reproductive tissues 
[134]. CB2 receptor is mainly expressed in periphery especially in lymphoid organs and 
immune cells but it was also identified in brain tissues [189]. 
Other difference between the two cannabinoid receptors is the physical association of 
CB1 with lipid rafts in several cell types, since these membrane microdomains are 
important for the modulation of its activity  [190-193].  In fact, it was reported that the 
disruption of lipid rafts with methyl-β-cyclodextrin enhances the AEA-induced effects 
through CB1 by interfering with mechanisms responsible for attenuation or termination of 
CB1 signalling [192]. On the other hand, cholesterol enrichment of plasma membrane 
reduced the CB1 receptor-dependent signal transduction, due to the increased rigidity 
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[194]. Also, lipid rafts are important for CB1 internalization by endocytosis [190, 195, 196], 
which leads to degradation in lysosomes or recycling, regulating CB1 levels in the cell 
membrane. On the contrary to CB1, CB2 binding and signalling is not dependent on the 
microarchitecture of the plasma membrane [197-199]. This may result from the putative 
cholesterol recognition amino acid sequence present in CB1 [200] or due to the post-
translational palmitoylation of this receptor [201], that seem to be important for CB1 
interaction with lipid rafts. Nevertheless, it was also described that lipid rafts disruption 
reverses AEA-induced cell death in different cell types, through receptor-independent 
mechanisms [138, 202, 203]. 
In the last years, evidences supporting the existence of other putative cannabinoid 
receptors have been emerged. The orphan GPCR, GPR55, is the best candidate to be 
considered the third cannabinoid receptor (CB3), since it seems to be activated by 
cannabinoid receptors agonists, including AEA and 2-AG [204].  
Besides cannabinoid receptors, it has been reported that endocannabinoids interact 
with other type of receptors and modulate the activity of ion channels. Transient Receptor 
Potential Vanilloid (TRPV1) is a non-selective cation channel belonging to the six-
transmembrane-domain Transient Receptor Potential (TRP) channels and it was identified 
in 1997 by Caterina et al. [205]. This receptor is activated by noxious heat (> 42 ºC), low 
pH (<6) and by several endogenous and exogenous molecules and its best known agonist 
is the capsaicin (CPS), an hot chilli pepper component [206]. TRPV1 is expressed in 
several organs and tissues among the body and participates in different physiological 
events. In fact, this receptor is mainly involved in temperature sensing [207] and 
nociception [205, 208, 209], but is also associated with other cellular processes such as 
apoptosis [153, 210, 211], muscle contraction [212-214], cell differentiation [215-217], 
autophagy [218, 219] and inflammation [208, 220, 221].  
It is known that AEA and 2-AG may also target the nuclear receptors PPARs involved 
in the regulation of metabolism and energy homeostasis, cell differentiation, 
immune/inflammatory responses and reproductive events. [162, 163, 222-224].  
 
 
2.3 Metabolism of Endocannabinoids 
The endocannabinoids, mainly AEA and 2-AG, are involved in several important 
physiological mechanisms, so their biosynthesis and degradation must be tightly regulated 
to maintain the homeostasis of endocannabinoid signalling.  
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2.3.1 Biosynthesis of Anandamide and other N-acylethanolamines 
N-acylethanolamines like AEA can be synthetized through multiple pathways (Figure 
6). They are originated from plasma membrane phospholipids [225] and their major 
biosynthetic pathway, transacylation–phosphodiesterase pathway, is catalysed by the 
enzymes N-acyltransacylase (NAT) and N-acylphosphatidoylethanolamine-Phospholipase 
D (NAPE-PLD). NAT is a calcium-dependent enzyme localized in cellular membranes, 
which transfers a fatty acid chain from sn-1 position of 1, 2-diacylglycerophospholipid (e.g. 
phosphatidylcholine –PC) to the amine group of phosphatidylethanolamine (PE). From 
this reaction results the precursor of NAE, N-acylphosphatidylethanolamine (NAPE), and 
a lysophospholipid [226]. NAPEs are biological constituents of plasma membrane and 
their levels are increased in inflammation and tissue degeneration [226]. 
The second step of NAE formation is catalysed by NAPE-PLD, a calcium-dependent 
and highly conserved enzyme belonging to the zinc metallo-β-lactamase family. This 
enzyme is also localized in biological membranes and converts N-
arachidonoylphosphatidylethanolamine (NArPE) into AEA and other NAPEs into their 
correspondent NAE, releasing phosphatidic acid [227].  
Although the transacylation-phosphodiesterase pathway is considered the major 
source of AEA, NAPE-PLD knockout mice revealed the existence of alternative 
biosynthetic pathways [228]. One pathway involves the double O-deacylation of NAPEs 
by the serine hydrolase α/β-hydrolase 4 (ABHD4), which is expressed in several organs. 
ABHD4 hydrolyses NAPE to lyso-NAPE and then lyso-NAPE to glycerophospho-N-
acylethanolamine (GP-NAEs) [229]. GP-NAE is finally converted into NAEs by the metal-
dependent GP-NAE phosphodiesterase, glycerophosphodiesterase 1 (GDE1) [230]. In 
addition, secreted Phospholipase A2 (sPLA2) is expressed in several rat tissues 
especially in stomach and is also able to convert NAPE to lyso-NAPE, which is then 
converted to AEA by lyso-Phospholipase D (lyso-PLD) [231].  
Another pathway of AEA synthesis involves the synthesis of phospho-N-
arachidonoylethanolamine (pAEA) by a not yet identified Phospholipase C (PLC)–like 
enzyme. pAEA is subsequently dephosphorylated by a protein tyrosine phosphatase 
(PTPN22), originating AEA. Inositol 5’-phosphatase SHIP1 also contributes to the 
synthesis of AEA from pAEA [232].  
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Figure 6. Biosynthetic pathways of Anandamide (AEA).  
AEA is produced from membrane phospholipids by NAT, resulting the intermediate NAPE. Then, NAPE is 
hydrolysed by several enzymes, being NAPE-PLD the major biosynthetic enzyme. ABHD4-α/β-hydrolase 4; 
ArPC- arachidonoylphosphatidylcholine; GDE1- glycerophosphodiesterase 1; GP-AEA- glycerophospho-AEA; 
lyso-NAPE- lysophosphatidyl-NAPE; lyso-PC- lysophosphatidylcholine; NAPE-PLD- N-
acylphosphatidylethanolamine-phospholipase D; NAT- N-acyltransferase; pAEA -phospho-AEA; PE-
phosphatidylethanolamine; PLC- phospholipase C; PTPN2- phosphatase protein tyrosine phosphatase 22; 
SHIP1- SH2 domain-containing inositol phosphatase. sPLA2-secreted phospholipase A2.  
 
 
2.3.2 Biosynthesis of 2-Arachidonoylglycerol  
The most significant biosynthetic pathway of 2-AG is a two-step reaction catalysed by 
PLC and Diacylglycerol Lipase (DAGL), which converts arachidonic acid-containing 
membrane phospholipids, such as phosphatidylinositol (PI) into 2-AG (Figure 7).  
PLC generates 1-acyl-2-arachidonoylglycerol or Diacylglycerol (DAG) and the latter is 
hydrolysed by DAGL [126, 233]. More recently, two DAGL enzymes (α and β) were cloned 
and characterized. They are expressed in the membrane fraction, their optimal activity is 
achieved at pH 7 and are stimulated by Ca2+ [179]. Alternatively, phospholipase A1 
(PLA1) can synthetize 2-arachidonoyl-lysophosphatidylinositol (lyso-PI), which is 
hydrolysed to 2-AG by lyso-PLC activity [234]. Under certain conditions, 2-AG can also be 
synthesized through the conversion of 2-arachidonoyl lysophosphatidic acid (LPA) by a 
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phosphatase [235]. Finally, the intermediate of 2-AG synthesis, DAG, can alternatively be 
produced from phosphatidic acid (PA) by PA hydrolase [236]. 
 
 
 
Figure 7. Biosynthetic pathways of 2-arachidonoylglycerol (2-AG).  
The main synthetic pathway is a two-step reaction involving the formation of intermediate DAG by PLC, 
followed by DAGL hydrolysis. Alternatively, PLA1 and Lyso-PLC can also synthetize 2-AG.  2-AG can also be 
produced from PA by PA hydrolase. DAG-diacylglycerol; DAGL-diacylglycerol lipase; Lyso-PI- lyso 
phosphatidylinositol; lyso-PLC-lysophosphatidylinositol phospholipase C; PA- phosphatidic acid; PI-
phosphatidylinositol; PLA1-phospholipase A1. 
 
 
 
2.3.3 Degradation of Anandamide and other N-acylethanolamides 
The pathways involved in AEA degradation are summarized in Figure 8. FAAH 
hydrolyses AEA to arachidonic acid (AA) and ethanolamine (EA) and is the most 
important degrading enzyme [237]. FAAH is a membrane-bound enzyme of the serine 
hydrolases family, achieves maximal activity at pH 9 and is a member of amidase 
signature family of enzymes characterized by a Ser241-Ser217-Lys142 catalytic triad 
[238]. This enzyme has been cloned in several species and has an ubiquitous expression, 
though it is preferentially expressed in brain, small intestine and testis [239, 240]. FAAH is 
expressed in intracellular membranes and is mainly found in microsomal and 
mitochondrial fractions [240]. It hydrolyses amides and esters at same rate, contrasting 
with other serine hydrolases, which express greater activity for esters [241].  
Recently, other isoform of FAAH, FAAH-2, was identified. These two isoforms are both 
members of amidase protein family, own an N-terminal transmembrane domain and share 
the Ser-Ser-Lys catalytic triad but only have approximately 20% of sequence identity 
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[239]. FAAH-2 is expressed in mammalian tissues but not in rodent tissues and it is the 
predominant isoform in heart and ovaries [239]. In contrast with FAAH-1, FAAH-2 is not 
localized in the endoplasmic reticulum (ER) and is expressed in cytosolic lipid droplets, 
suggesting that these enzymes may have different physiological roles [242]. In addition, 
FAAH-2 is much less effective than FAAH-1 at hydrolysing NAEs [239], but its expression 
in peripheral tissues suggests that this molecule might have a rescue role in NAEs 
hydrolysis upon FAAH inactivation [238]. Moreover, C-terminal catalytic domains of 
FAAH-1 and FAAH-2 are in cytoplasmic and luminal compartments of the cells, 
respectively, suggesting that this opposite orientation might influence their access to 
specific fatty acid amide substrates in cells, especially if these lipids show preferential 
localization to the inner or outer leaflet of the membrane bilayer [239].  
 
 
 
Figure 8. Inactivation pathways of Anandamide (AEA).  
AEA can be inactivated by hydrolysis to AA and EA by FAAH-1 (the major pathway), FAAH-2 and NAAA or 
can be oxidized by COX-2, 12- and 15-LOX or CYP450. AA-arachidonic acid; COX-2-cyclooxigenase 2; 
CYP450-cytochrome P450; EA-ethanolamine; FAAH 1/2-fatty acid amide hydrolase 1/2; 12-, 15-HETE-EA-
12-, 15-hydroxyeicosatetraenoic acid ethanolamide;12-,15-LOX-12-,15-Lypoxigenase; NAAA- N-
acylethanolamine-hydrolysing acid amidase; PGH2-EA- prostaglandin-ethanolamides.  
 
 
 
N-acylethanolamine-hydrolysing acid amidase (NAAA) is an acid ceramidase-like 
protein that hydrolyses NAEs. The first evidences of the existence of NAAA emerged with 
the report of a FAAH-distinct AEA hydrolysis activity in human megakaryoblastic cell line 
[243]. NAAA is mainly localized in lysosomes, is self-activated by a acid pH-dependent 
proteolytic cleavage and has a cysteine residue responsible for its catalytic activity [244]. 
Besides hydrolysis, AEA may also be metabolized by the same enzymes that are 
responsible for the oxidation of arachidonic acid, including Cyclooxygenase-2 (COX-2), 
12- and 15-Lipoxygenase (12-LOX, 15-LOX) and Cytochrome P450 (CYP450). COX-2 
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oxidizes AEA to several oxygenated products (prostaglandin-ethanolamides (PG-EA) or 
prostamides) [245]. Although their lack of affinity for CB receptors [246], some of these 
metabolites are provided with biological activity, mediating AEA-induced apoptosis [247-
250] and inflammation [251, 252]. 12- and 15- LOX induce a hydroxylation in the AEA 
molecule, forming the hydroperoxides 12- and 15-hydroperoxyeicosatetraenoic acid 
ethanolamide (12-HPETE-EA, 15-HPETE-EA), which will be enzymatically or chemically 
reduced to the corresponding hydroxyeicosatetraenoic acid, 12-HETE-EA and 15-HETE-
EA [253]. LOX metabolites of AEA seem to be agonists of TRPV1 receptor [254] and are 
powerful natural inhibitors of FAAH, controlling AEA degradation [255]. Also, 12-HETE-EA 
binds to CB receptors with an affinity similar to that of AEA [256]. CYP450 is also able to 
oxidize AEA to epoxyeicosatetraenoyl-ethanolamides and one of these compounds is able 
to activate CB2 receptor [257]. 
 
 
2.3.4 Degradation of 2-Arachidonoylglycerol 
The major enzyme responsible for 2-AG degradation is the serine hydrolase 
Monoacylglycerol Lipase (MAGL). This enzyme cleaves 2-AG into AA and glycerol, owns 
a Ser122-His269-Asp239 catalytic triad and is ubiquitously expressed [258]. In brain, 
MAGL is localized in presynaptic neurons so, it has been pointed as the pivotal enzyme 
controlling the duration of 2-AG-mediated retrograde signalling [259]. MAGL is localized in 
cytosol and is responsible for 85% of degradation of 2-AG in rat brain [260]. The 
remaining 15% are mostly catalysed by the enzymes α/β-hydrolase domain 6 and 12 
(ABDH6, ABDH12). Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular 
distributions, suggesting that they may control distinct pools of 2-AG in the nervous 
system [261]. Moreover, 2-AG is also a substrate for FAAH due to the esterase activity of 
this enzyme [262] and, although FAAH seemed to have a reduced contribution for 2-AG 
hydrolysis in brain [261], recent evidences pointed that FAAH is relevant for the regulation 
of 2-AG levels in hepatic cells [263]. 
Similarly to AEA, 2-AG may also be oxidized by COX-2, 12- and 15-LOX. COX-2 
converts 2-AG to Prostaglandin-glyceryl esters (PG-GE), like PGE2-GE [264], while the 
oxidation by 12- and 15-LOX produces 12- and 15-hydroperoxyeicosatetraenoic acid 
glycerol ester (12-HPETE-GE, 15-HPETE-GE), respectively, which will originate the 
corresponding hydroxyeicosatetraenoic acids, 12-HETE-GE and 15-HETE-GE [253].. 
Some of these oxygenated metabolites have biological activity [265-268]. 15-HETE-GE 
seems to have a biological role due to its agonist activity in PPAR-α [269]. LOX 
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metabolites of 2-AG were found to be powerful natural FAAH inhibitors and might play a 
role in controlling AEA degradation [255]. CYP450 can also oxidize 2-AG and the 
produced metabolites play a role in Ca2+-induced relaxation of rat mesenteric arteries 
[270]. The degradation pathways of 2-AG are resumed in Figure 9. 
 
 
 
Figure 9. Inactivating pathways of 2-AG.  
2-AG is mainly hydrolysed by MAGL to AA and glycerol but ABHD6/12 can also hydrolyse this EC. In addition, 
2-AG might also be oxidized by COX2, 12- and 15-LOX and CYP450. AA-arachidonic acid; ABHD6/12-α/β-
hydrolase 6/12; CYP450-cytochrome P450; COX-2-cyclooxigenase 2; 12-,15-HETE-GE-12-,15-
hydroxyeicosatetraenoic acid glycerol ester; 12-,15-LOX- 12-,15-Lypoxigenase; MAGL-monoacylglycerol 
lipase; PGH2-GE- prostaglandin-glycerol esters.  
 
2.3.5 Release and Uptake of Endocannabinoids 
After biosynthesis, eCBs are released to extracellular space to activate CB receptors 
either by membrane diffusion or by a transporter, or they can act inside the cell through 
TRPV1 or PPARs activation. Cessation of cannabinoid signalling occurs through a two-
step process comprising the transport of eCBs from the extracellular to the intracellular 
space followed by degradation through hydrolysis or oxidation. It has been proposed that 
eCBs are able to diffuse through cell plasma membrane due to their lipophilic nature but, 
on the other hand, other data indicate that the uptake of eCBs is a transmembrane 
protein-facilitated process [271].  
For years, it has been proposed that AEA crosses cell membrane by a membrane-
localized protein carrier, the EMT. This transporter has been characterized as 
temperature-dependent, saturable, bidirectional and energy-independent, however, the 
type of protein involved is not yet identified [272-274]. Recently, Fu et al. identified a 
truncated variant of FAAH-1 in neurons. This protein was designated FAAH-1 like 
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anandamide transporter (FLAT), lacks amidase activity but binds to AEA, facilitating its 
uptake [275]. However, other results raised questions about FLAT as an AEA intracellular 
transporter, since they reported that this protein has residual catalytic activity and is 
localized in intracellular membranes [276]. 
The simple diffusion is another proposed mechanism of AEA uptake, since it can 
interact with membrane phospholipids and the membrane cholesterol seems to facilitate 
AEA uptake [192, 277]. Therefore, some authors defend that there is no membrane 
protein carrier and that the transport of AEA across cell membrane is conditioned via its 
intracellular hydrolyses by FAAH and/or its intracellular sequestration [278]. The 
continuous degradation by FAAH maintains the concentration gradient necessary to drive 
the process of simple diffusion [274, 278]. However, other data reported that FAAH is not 
the only responsible for eCBs uptake, as cells and tissues of FAAH knockout mice are 
also able to accumulate AEA by a saturable, selective, pharmacologically inhibited and 
bidirectional mechanism [272]. 
The intracellular sequestration of eCBs by binding to intracellular proteins has also 
been suggested as a mechanism for eCBs uptake [279] but only, recently, these proteins 
were identified. AEA can interact with soluble carrier proteins facilitating the trafficking of 
AEA. In fact, albumin, Heat Shock protein 70 (HSP 70), Fatty Acid Binding proteins 5 and 
7 (FABP5, FABP7) and FLAT are Anandamide Intracellular Binding Proteins (AIBP) and 
seem to have an important role in intracellular sequestration, rapid and efficient 
distribution of AEA to the different intracellular compartments [157, 158, 275]. Very 
recently, it was also found that the sterol carrier protein-2 may participate in AEA’s cellular 
uptake though, due to its low affinity for this eCB, it does not contribute significantly to its 
intracellular sequestration [280]. Furthermore, AEA can also be accumulated in 
adiposomes [156] and so its half-life inside the cell may be extended, in order to achieve 
higher concentrations and last long enough to activate nuclear PPARs. Therefore, it has 
been proposed that AIBP may act as anandamide intracellular transporters, carrying AEA 
to different cellular compartments, like adiposomes, where it can be accumulated and/or 
degraded by FAAH, COX-2 and 15-LOX, enzymes that may also be localized in these 
cellular structures [165]. This intracellular sequestration supports the simple diffusion of 
AEA, since the removal of free AEA from the intracellular pool promotes the inward 
concentration gradient and, consequently, the AEA uptake [279]. On the other hand, 
recently, it was reported that EMT transport is independent from AIBPs or degrading 
enzymes [281].  
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In addition, AEA uptake can also occur via a protein-carrier-mediated caveolae-related 
endocytosis. This process proposes that AEA binds a carrier protein located within the 
caveolae, a caveolae-derived vesicle (clathrin-independent) is formed and, subsequently, 
AEA endocytosis occurs; this process is rapid, saturable and energy independent [282]. In 
this way, the eCBs uptake is still poorly understood and more information about this 
process is required. Figure 10 resumes the proposed pathways of AEA transport across 
cell membrane and a model of intracellular trafficking of AEA.  
 
 
 
Figure 10. The proposed models for AEA uptake and intracellular traffic.   
After activating cannabinoid receptors in extracellular environment (CBR), AEA can passively diffuse across 
cellular membrane due to a concentration gradient (represented at left, in dark blue). AEA may be transported 
into the cells via a protein carrier-mediated caveolae-related endocytosis (represented in centre, in blue). 
Endocannabinoid Membrane Transporter (EMT) may facilitate the internalization of AEA (represented at right, 
in light blue). AEA may be sequestered inside the cell by binding to AEA Intracellular Binding Proteins (AIBPs) 
or stored in adiposomes, which may also interact with AIBPs. Moreover, FAAH-like AEA transporter (FLAT) 
may also participate in AEA uptake. All these proteins may distribute AEA throughout the cytoplasm and cell 
organelles, facilitating its degradation by fatty acid amide hydrolase (FAAH). Inside the cell, AEA can also 
activate the transient receptor potential vanilloid 1 (TRPV1) or nuclear receptors [134]. 
 
 
The majority of these models were suggested after studies of AEA transport however, 
there are evidences that suggest that AEA and 2-AG are accumulated in cells via 
common mechanisms. Moreover, 2-AG inhibits AEA cellular uptake indicating a 
competitive nature of the transport of these two eCBs [271]. 
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2.4 Endocannabinoid Signalling 
Cannabinoid receptors are expressed in several cells and tissues in the organism. 
Along with their agonists, CB receptors are crucial for the transduction of 
endocannabinoid signalling, which modulates multiple cellular pathways in different 
physiological and pathophysiological mechanisms. The signalling pathways affected after 
CB receptors activation are summarized in Figure 11.    
CB receptors are generally coupled to Gi/0 proteins, triggering several cellular 
mechanisms, like AC inhibition, MAPK activation, activation of inward rectifying K+ (Kir) 
channels or inhibition of voltage-gated Ca2+ channels [283, 284]. The coupling of CB1/2- 
Gi/0 was demonstrated by the impairment of these effects after treatment with PTX, a 
specific inhibitor of Gi/0 proteins [186, 283, 285]. Nevertheless, under conditions of PTX 
treatment, CB1 but not CB2 may interact with Gs [286] and Gq/11 [287] proteins leading to 
different cellular effects. 
The inhibition of some AC isoforms by Gi/0 proteins-coupled to CB receptors results in a 
decrease of cAMP levels, a second messenger that stimulates the activity of Protein 
Kinase A (PKA). Consequently, reduced PKA activity impacts important cellular signalling 
events including voltage-dependent current flow at A-type K+ channels [288] and focal 
adhesion kinase (FAK) phosphorylation [289]. Besides Gi/0, CB1 may also be coupled to 
Gs proteins [290]. Recently, it has been described that CB receptors activation induces the 
phosphorylation of cAMP response element binding protein (CREB) [291, 292]. 
MAPK pathway regulates cellular functions such as proliferation, differentiation and 
apoptosis. CB1 and CB2 activation increases the phosphorylation of p38 [293-297], ERK 
1/2 [298-302] and c-Jun N-Terminal Kinases (JNK) [296, 303, 304]. Moreover, CB 
receptors activation enhances [305, 306] or inhibits the Phosphoinositide 3-kinase  (PI3K)/ 
Protein Kinase B (PKB or Akt) [307]. 
Cannabinoid agonists regulate ionic channels through activation of CB1. In fact, they 
inhibit voltage-gated calcium channels (VGCC) of most types including P/Q, N and L-type 
channels by a mechanism mediated by Gi/0 proteins [308-310]. T-type Ca2+ channels are 
also inhibited by AEA through direct binding [311]. Furthermore, CB1 activation promotes 
the stimulation of Kir channels, also in a Gi/0-dependent way [312]. TWIK-related acid-
sensitive K+ channels 1 (TASK-1), which are responsible for setting membrane potential, 
are inhibited by AEA and other CB agonists [313]. CB receptors activation may also 
increase intracellular Ca2+ concentrations through different pathways that aims the release 
of Ca2+ from IP3-sensitive stores [314-316]. 
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Figure 11. Cannabinoid signalling pathways resulting from the activation of CB receptors coupled to G 
protein.  
The inhibition of AC induces a decrease in cAMP levels, leading to a decrease in PKA activity. CB1 also 
mediates the stimulation of intracellular kinases such as ERK, JNK, p38, FAK and PI3K/AKT, which are 
involved in several intracellular mechanisms. Ionic channels can also be regulated by cannabinoid signalling 
receptors: Ca2+ channels inhibited whereas K+ channels are induced after the activation of CB1. Moreover, the 
intracellular levels of Ca2+ are increased. The binding of the adaptor protein FAN to CB1 induces ceramide 
accumulation through the stimulation of SM hydrolysis by SMase. Also, CB1 can stimulate de novo synthesis 
of ceramide by SPT, from FA and Ser. AC-Adenylyl Cyclase; ERK- Extracellular signal-regulated kinase; FA- 
fatty acid; FAK- focal adhesion kinase; FAN- factor associated with neutral sphingomyelinase activation; JNK-
c- Jun N-Terminal Kinases; PI3K-Phosphoinositide 3-kinase; PKA-Protein Kinase A; Ser- serine; SM-
sphingomyelin; SMase-Sphingomyelinase; SPT- serinoylpalmitoyltransferase.  
 
 
The adaptor protein factor associated with neutral sphingomyelinase activation (FAN) 
is also able to interact with CB1, mediating its interaction with sphingomyelinase (SMase), 
the enzyme that hydrolysis sphingosine into ceramide. In this way, CB1 triggers an acute 
generation of ceramide, which is related to the regulation of metabolic functions. 
Nevertheless, activation of CB1 also induces a long term ceramide accumulation due to 
the stimulation of its de novo synthesis by serine palmitoyltransferase [317]. Ceramide 
mediates CB1-induced apoptosis in several cell types [297, 318-321]. Besides CB1, CB2 
also stimulates ceramide synthesis, inducing apoptosis [155, 321].  
Recently, some proteins that specifically interact with CB1 were discovered. CB1 
receptor interacting proteins, CRIP1a and CRIP1b, bind to CB1 C-terminal but, till now, 
only CRP1a effects on modulation of CB1 activity were recognized [322]. G protein-
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coupled receptor associated sorting protein 1 (GASP1) interacts with CB1 receptor, 
inducing its downregulation and regulating its post-endocytic targeting to lysosome [323]. 
β-arrestins are also involved in desensitization of CB1 receptor, since they bind to agonist-
occupied CB1, preventing the signal transduction and initiating the endocytosis of CB1-
arrestin complex [324]. Since some of these proteins reside within or depend on lipid rafts, 
it is possible that the disruption of these structures could negatively influence CB1 
desensitization, exacerbating CB1 signalling [325].  
 
 
2.5 Endocannabinoid system in cell death 
Cell death is a cellular event that is crucial for the homeostasis of tissues and organs, 
while unbalanced cell death rates are associated with several pathological conditions such 
as cancer, neurodegenerative diseases and pregnancy-related complications. The ECS 
has emerged as an important intervener in cell death processes like apoptosis, necrosis 
or autophagy. 
Apoptosis is a programmed cell death mechanism by which cells die without damaging 
the neighbouring cells. This is an ATP-dependent process and occurs mainly by two major 
apoptotic pathways, the mitochondrial and the death receptor pathways. Cells undergoing 
apoptosis own morphological characteristic features such as chromatin condensation and 
fragmentation and membrane blebbing. The pro-apoptotic effects of AEA have been 
described in several cell types, through CB receptor-dependent and independent 
mechanisms, triggering different downstream signalling pathways. In fact, after binding to 
CB1 or CB2, AEA induces apoptosis by activation of caspase-9, loss of ∆ψm, oxidative 
stress and ceramide accumulation [297],  as well as, cytochrome c release [155, 192, 326] 
or intracellular Ca2+ levels increase [327]. Also, AEA-induced apoptosis may require the 
phosphorylation of p38, ERK1/2 or JNK [297, 326-329], which may occur directly after 
CB1 activation or ceramide accumulation. Besides AEA, 2-AG can also induce apoptosis 
in some cell types, such as decidual cells [175] and hepatic stellate cells [178], through 
the activation of mitochondrial pathway.  
CB1 and CB2 activation may also trigger an apoptotic mechanism mediated by the 
endoplasmic reticulum (ER) stress. In fact, in human pancreatic tumor cells, a CB2 
receptor-dependent accumulation of de novo synthetized ceramide upregulates the 
stress-regulated protein p8, the ER stress-related genes activating transcription factor 4 
(ATF-4) and telomere repeat binding factor 3 (TRIB-3) [330].  
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Most of the abovementioned apoptotic mechanisms involve the activation of the 
mitochondrial pathway. Nevertheless, eCBs may also trigger the death receptor pathway. 
In fact, in cholangiocarcinoma cells, AEA causes apoptosis through a CB receptor-
independent mechanism, by accumulation of ceramide and recruitment of Fas and FasL 
into lipid rafts [331] and recently, these effects were attributed to the activation of GPR55 
[332]. In Chang liver cells, AEA mediates cell death by activation of both extrinsic and 
intrinsic pathways, with upregulation of FasL, Bim and Bax [333]. The CB2 agonist JWH-
015 and THC also induce apoptosis in immune cells, through a crosstalk between 
extrinsic and intrinsic pathways with activation of caspases-3,-8 and -9 and loss of ∆ψm 
[334, 335]. In addition, in chondrocytes, Gomez et al. reported that AEA induces apoptosis 
through a CB receptor-independent mechanism that also involves an interplay between 
intrinsic and extrinsic pathways [154]. In addition, the activation of TRPV1 by AEA triggers 
the mitochondrial pathway in human neuroblastoma and lymphoma cells [336] and, in 
human endothelial cells, AEA-induced activation of TRPV1 leads to apoptosis by a 
mechanism dependent on p38 and JNK phosphorylation [337].  
A role for COX-2 oxygenated metabolites of AEA, the prostamides, in cell apoptosis 
has recently emerged. In keratinocytes, AEA mediates apoptosis after being metabolized 
to J-series prostaglandins, which generate oxidative stress [250]. Moreover, the AEA-
induced cell death in colon cancer cells is also dependent on COX-2 but independent on 
oxidative stress [249]. Recently, in melanoma cells, it was reported that AEA proapoptotic 
effects are, at least partially, mediated by COX-2 and also LOX metabolites [338]. 
The eCBs have also been associated with necrosis. In fact, AEA and 2-AG induce 
necrosis in rat decidual cells [138, 175]. AEA induces necrosis in hepatic stellate cells, by 
increasing intracellular Ca2+ levels and oxidative stress [339] and through the 
downregulation of the prosurvival pathway PI3K/Akt and induction of inflammatory 
cytokines production [202].  
Autophagy is a cellular event pivotal for cell homeostasis that is involved in both cell 
survival and death. It consists in enclosing cellular components into autophagosomes 
(double-membrane vesicle), which will fuse with lysosomes to be degraded and recycled. 
Recently, new data have reported the involvement of the endocannabinoid signalling in 
autophagy-related apoptosis. In fact, THC stimulates de novo synthesis of ceramide via 
CB1 in glioma cells, initiating an ER stress response, which induces autophagy via TRIB3-
dependent inhibition of Akt/mTORC1 (mammalian target of rapamycin complex 1) axis, a 
repressor of this cellular event. Moreover, it was reported that autophagy is required for 
the cannabinoid antitumoral action, since it was crucial for the activation of the 
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mitochondrial pro-apoptotic pathway [340]. In hepatocellular carcinoma, THC and CB2 
agonist JWH-015 induce an autophagic process that is also important for cell apoptosis. 
Here, autophagy is induced either by activation of adenosine monophosphate-activated 
kinase (AMPK) or by ceramide accumulation. The latter leads to TRIB3 activation, 
inhibiting Akt/mTORC axis and activating PPAR-γ, which leads to autophagy and then to 
cell apoptosis [341, 342].  
In addition to the aforementioned cell death mechanisms, in some types of mantle 
lymphoma cells, the CB1 agonist WIN55-212,2 induces paraptosis, a non-apoptotic 
programmed cell death mechanism characterized by the presence of cytoplasmic 
vacuoles of ER origin, which differ from the autophagic vacuoles, since they do not fuse 
with lysosomes [343].  
In summary, the participation of endocannabinoid signalling in different cell death 
processes seems to be cell specific, since it may trigger different cell death pathways and 
interfere with several cellular signalling mechanisms.  
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3. Endocannabinoids in reproduction 
The hazards of Cannabis sativa in reproductive function are known for years. Its major 
psychoactive component, THC, induces a decline in pituitary hormones, follicle stimulating 
hormone (FSH), luteinizing hormone (LH) and prolactin, and also in sex hormones, 
progesterone, oestrogens, and androgens, having a negative outcome in fertility. THC 
also inhibits ovulation, crosses placenta and can accumulate in maternal milk [344-346]. 
The consumption of cannabis during gestation is implicated in deficient foetal growth, low 
birth weight, preterm labour and long-term neurobehavioral disturbances [347, 348]. With 
the discovery and identification of CB receptors and their endogenous compounds that 
are capable of mimicking the THC effects, an interest in the study of their implications in 
physiologic and pathophysiologic mechanisms has emerged. Also, CB receptors are 
present in female and male reproductive organs and tissues like ovaries, uterus, placenta, 
testis, prostate, sperm and embryo. Thus, ECS has been a target for the study of male 
and female fertility and of different stages of pregnancy like preimplantation, implantation, 
decidualization, placentation, foetal development and labour. Figure 12 summarizes eCBs 
effects on these reproductive events. 
 
 
3.1 Endocannabinoid system in female reproductive tract and 
fertility 
The presence of eCBs in several female reproductive tissues, organs and fluids 
suggests a role for this system in physiological reproductive processes. AEA is present in 
mid-cycle oviductal fluid, follicular fluid, amniotic fluid, milk and in human seminal plasma, 
suggesting a role for AEA in modulation of multiple physiological and pathophysiological 
processes, such as follicular maturation, ovulation, placental and foetal development and 
lactation.  
Human ovaries express both cannabinoid receptors in cortex and medulla and CB2 
expression is generally higher. FAAH and NAPE-PLD are expressed only in secondary 
and tertiary follicles, corpus luteum and corpus albicans, which enable the AEA synthesis 
in the ovaries [349]. Peralta et al. recently demonstrated that human oocytes express CB1 
and CB2 and that their localisation change during the various stages of meiotic 
resumption [350]. During the menstrual cycle, plasmatic AEA levels suffer alterations, 
peaking in the early follicular phase [351]. Moreover, the plasmatic peak of AEA is 
achieved at the ovulation and, then, AEA levels decrease in early luteal phase [352]. 
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During menstrual cycle, it is also verified a correlation between AEA levels and oestradiol, 
FSH and LH suggesting that these hormones may have a role in regulation of this eCB 
[352]. In the periovulatory phase, while progesterone synthesis is supressed, the lowest 
levels of this hormone coincide with lowest levels of FAAH. Also, both molecules reach 
maximal values at luteal phase. [353]. Together, these data suggest a role for 
endocannabinoid system in folliculogenesis, follicle and oocyte maturation and ovulation. 
 
 
Figure 12. Schematic representation of endocannabinoids (eCBs) effects throughout pregnancy and 
the negative impact of an abnormal endocannabinoid signalling.   
Decidual cells result from the differentiation of endometrial stromal cells, in order to turn the uterus receptive to 
the implanting embryo. Trophoblast cells proliferate, differentiate, invade maternal tissues and undergo 
apoptosis, allowing the placental development. Emerging data indicate that eCBs are part of the complex 
network of hormones, cytokines and other molecules that regulate the reproductive events, namely 
implantation and decidualization. Furthermore, it is suggested that an abnormal endocannabinoid signalling 
(yellow boxes)  may be involved in the pathophysiology of pregnancy-associated complications, such as  
intrauterine growth restriction, preeclampsia and spontaneous abortion [354]. 
 
The members of ECS are also expressed in human uterus, during menstrual cycle. 
CB1 and CB2 receptors are widely distributed in uterine tissues. CB1 is expressed with 
higher intensity in endometrial glands than in stromal cells, whereas CB2 receptor 
immunoreactivity is minimal at the beginning of a new cycle, increasing till its maximal 
expression in late-proliferative phase. Moreover, it was verified an increase of FAAH and 
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a decrease in NAPE-PLD expression during menstrual cycle in endometrium till mid-
secretory phase [355]. Recently, Scotchie et al. corroborated some of these findings 
reporting that FAAH expression was enhanced in secretory phase but they also reported 
augmented NAPE-PLD expression. Moreover, they described an increased expression of 
MAGL and COX-2 in this phase, supporting that low levels of 2-AG may also be required 
during the implantation period [356]. 
The eCBs seem also to have a role in the regulation of human myometrial function. In 
fact, in the human myometrial smooth muscle cell line ULTR, AEA activates ERK1/2 
pathway in a CB1-dependent mechanism and inhibits AC, inducing cell viability loss [357]. 
Recent data, in human myometrium, reported that NAPE-PLD, FAAH and CB1 are 
expressed but TRPV1 and CB2 are absent in this tissue [358]. 
In endometrial stromal cells, the non-hydrolysable AEA analogue methananadamide 
induces cell migration via CB1-dependent activation of PI3K/Akt and ERK1/2 pathways 
[359]. Moreover, methanandamide enhances ESC proliferation and, longer exposures, 
induces apoptosis [360].  
During human ovulatory cycle, there are oscillations in the levels of AEA and FAAH in 
peripheral lymphocytes. The expression of NAPE-PLD, EMT and CB receptors remain 
constant during the cycle [353]. The highest FAAH levels and the concomitant lowest AEA 
levels are found in the luteal phase, suggesting that these levels may be important for a 
successful implantation [353, 361].  
The evidences of interplay of sex steroids, cytokines and eCBs result essentially from 
the modulation of FAAH, the major controlling enzyme of AEA, by oestrogen, 
progesterone, leptin and Th cytokines, indicating a role for eCBs-hormone-cytokines in the 
regulation of human fertility [362]. Maccarrone et al. demonstrated that progesterone 
stimulates FAAH activity in human lymphocytes [363]. In addition, profertility Th2 
cytokines (IL4, IL10) stimulate FAAH activity whereas the antifertility Th1 cytokines (IL2, 
IL12 and interferon γ) have the opposite effect [363]. It was already verified that the 
activation of FAAH by progesterone results from an increase of nuclear levels of 
transcription factor Ikaros, which binds to FAAH promoter, inducing FAAH gene 
expression [364]. The adipokine leptin also induces activation of FAAH in human T 
lymphocytes through the activation of signal transducer and activator of transcription 3 
(STAT3), which upregulates a cAMP response element (CRE)-like site in FAAH promoter 
[365]. Thus, leptin and progesterone seem to exert a synergic effect in FAAH upregulation 
and consequently in the modulation of AEA levels. Furthermore, leptin and progesterone 
upregulate FAAH activity in human lymphoma cell line U937 [366]. Moreover, since they 
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decrease AEA levels, leptin and progesterone have a protective role in immune cells 
through the inhibition of AEA pro-apoptotic effects [367]. In addition, in the uterus of leptin 
knockout mice, AEA and 2-AG levels are elevated comparatively with wild-type mice, due 
to the decreased FAAH and MAGL activities and higher activity of DAGL [368]. Together, 
the data suggest that leptin and progesterone may interfere with the endocannabinoid 
signalling, reinforcing that abnormal levels of these hormones may be implicated in 
infertility. Figure 13 schematises the network in human lymphocytes, where FAAH has a 
central role. 
 
 
 
Figure 13. Role of Endocannabinoid system in hormone-cytokine network. 
After its biosynthesis, AEA is released in the intracellular space, where it activates CB1 and, among other 
actions, inhibits LIF release. AEA is transported into the cell via the putative EMT and is hydrolysed by FAAH 
to AA and ethanolamine. FAAH is upregulated by a synergic process mediated by progesterone and leptin. 
Progesterone binds to its intracellular receptor and upregulates the FAAH promotor through the transcription 
factor Ikaros (Ik). Leptin activates its membrane receptor, leading to the activation of STAT3, which will bind to 
CRE-like site, activating the transcription of FAAH gene. Moreover, FAAH activation by progesterone is 
enhanced by Th2 cytokines and inhibited by Th1 cytokines. AA- arachidonic acid; AEA- anandamide; CRE- 
cAMP response element; EMT- endocannabinoid membrane transporter; FAAH- fatty acid amide hydrolase; 
Ik- Ikaros; LIF-leukemia inhibitory factor; STAT3- signal transducer and activator of transcription 3. 
 
38 
 
Leukemia Inhibitory Factor (LIF) is a member of IL-6 cytokine family produced by T 
lymphocytes, which is important for a successful pregnancy. Indeed, LIF promotes 
embryo implantation and survival, is involved in the decidualization process and 
stimulates hCG production by trophoblasts [369]. Uterine levels of AEA are higher in LIF-
deficient mice [370]. Furthermore, AEA and 2-AG decrease the release of LIF through 
activation of CB1 and so, low FAAH activity may negatively impact the pregnancy 
outcome due to the reduction of LIF levels [363].  
 
 
3.2 Preimplantation 
Preimplantation is the reproductive event where the embryo begins its development. 
Mouse uterus and oviduct express the enzymatic machinery necessary for the synthesis 
of AEA [371, 372]. The preimplantation mouse embryo expresses mRNA of both CB 
receptors. In vitro, CB1 receptor agonists arrest the development of 2-cell embryos, inhibit 
the compaction and reduced the trophectoderm cells number [373, 374]. Moreover, the 
development of preimplantation embryo became asynchronous in CB1 or CB2 receptor 
deficient mice [370]. Recent evidences support that high levels of methanandamide, a 
CB1 agonist, induce autophagic activation and apoptosis in mouse blastocyst [375]. All 
these results suggest that deregulated endocannabinoid signalling via CB1 receptor 
impairs preimplantation process and consequently pregnancy course.  
The embryo transport along the oviduct to the uterus is achieved by a sequence of 
controlled contractions and relaxations of oviduct smooth muscle. Alterations in 
expression of CB1 receptor impairs the coordinated muscle contraction and relaxation, 
inducing embryo retention and possibly leading to implantation failure in mice [376]. In 
mouse oviduct, a balance between the expression of NAPE-PLD and FAAH is required to 
create locally an appropriate “anandamide tone” for normal development of embryos and 
their oviduct transport. NAPE-PLD is present in embryos during preimplantation period, 
since fertilization till the blastocyst stage, while FAAH is first expressed in 2-cell embryos. 
In the oviduct, it was verified an inverse distribution of these enzymes on days 1-4 of 
pregnancy: NAPE-PLD is expressed in higher levels in epithelium of the isthmus than of 
the ampulla, while FAAH levels are higher in the ampulla epithelium than in the isthmus. 
Furthermore, FAAH inactivation and the concomitant high AEA levels induce a retarded 
development, oviduct retention of embryos and impaired implantation through CB1 
receptor activation [377]. This suggests that FAAH is a key regulator of AEA tone and 
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CB1-activated pathways, which are crucial for the oviductal transport and must be tightly 
controlled to achieve a successful pregnancy.  
The embryo retention in fallopian tubes resulting from a dysfunctional muscle 
contraction is one of the causes of human ectopic pregnancy. In women with this 
pregnancy disorder, the expression of CB1 mRNA is lower in fallopian tubes and decidua, 
in comparison with normal pregnancy [378]. Gobeh et al. also reported that AEA levels 
were increased in ectopic fallopian tubes, whereas CB1 and FAAH expression was 
decreased [379]. In addition, FAAH activity was decreased in peripheral blood cells of 
women with ectopic pregnancy and AEA blood levels were increased [380].  
 
 
3.3 Implantation and embryo development 
Implantation is one of the most critical pregnancy events and requires a synchronized 
interaction between the trophoblast cells of activated blastocyst and the receptive uterus, 
which allows a suitable attachment of blastocyst. This event should occurs within the 
period of time where the activated stage of the blastocyst is superimposed on the 
receptive state of the uterus, the window of implantation [381]. The implantation process is 
highly regulated and it is proposed a role for ECS in this process. Indeed, in mouse 
uterus, AEA levels are spatiotemporal regulated during the gestational period. Down-
regulated levels of AEA detected at implantation sites are associated with uterine 
receptivity [382]. Higher faah and low nape-pld mRNAs in non-implantation sites correlate 
with the refractory uterus to embryo implantation and with low FAAH and NAPE-PLA 
expression [383-385]. Moreover, AEA reduces the zona-hatching of blastocysts and 
inhibits the implantation through CB1 activation [382]. In contrast, low AEA levels promote 
blastocyst attachment, accelerate trophoblast differentiation and outgrowth via CB1 
receptor activation but higher AEA levels impair these processes [386, 387]. This dual 
AEA effect results from the activation of two independent signalling pathways. In fact, low 
AEA concentrations promote blastocyst implantation through ERK phosphorylation in 
trophectoderm cells, while higher concentrations inhibit the activity of Ca2+ channels, 
hampering the implantation [141]. Moreover, uterine AEA levels and CB1 expression in 
the blastocyst are down-regulated prior to the implantation in mice, whereas in non-
receptive uterus and dormant blastocysts, their levels are higher, supporting a role for the 
endocannabinoid signalling in embryo synchronization with the uterine receptivity [370]. 
The other major eCB, 2-AG has the same expression pattern as AEA i.e., lower levels at 
implantation sites and higher at interimplantation sites, possibly also participating in 
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regulation of window of implantation [174]. Further, the expression pattern of 2-AG 
metabolic enzymes was also in agreement with the required low levels of eCBs at 
implantation sites: low levels of DAGL-α and high MAGL levels. In addition, COX-2 is 
expressed at implantation sites but is almost undetectable at interimplantation sites, which 
indicate a contribution of this enzyme in differential regulation of AEA and also points to a 
role for COX-2 derived prostaglandins in implantation [174].  
Mouse blastocysts release a soluble lipid compound that increases the activity but not 
the expression of uterine FAAH enzyme by 2, 5-fold. The FAAH activator is produced by 
trophoblasts and ICM and suggests that blastocysts may protect themselves from the 
toxic effects of high AEA uterine levels [388].  
In women that underwent in vitro fertilization/intracytoplasmic sperm injection 
(IVF/ICIS)-embryo transfer, it was verified that AEA plasma levels of pregnant women 
decreased from the day of oocyte retrieval to that of embryo transfer, increasing till 4-5 
weeks of gestation and achieving minimal values at 6 weeks. In contrast, in non-pregnant 
women, the lowest levels of AEA in plasma were registered in the day of oocyte retrieval 
and the decline till the embryo transfer was not observed [389]. These observations 
suggest that high levels of AEA in ovulation and lower levels in implantation period are 
required for a successful pregnancy in humans, as occurs in rodents. Also, during 
menstrual cycle, AEA plasma levels decreased in early luteal phase, coinciding with the 
window of implantation and reinforcing that low levels of AEA are beneficial to embryo 
implantation [352]. In summary, abnormal expression of AEA metabolic enzymes in uterus 
induce a deregulation of AEA levels that may lead to a deficient implantation and, 
consequently, to complications during gestation. 
 
 
3.4 Endocannabinoid system and pregnancy maintenance 
The ECS may also have a fundamental role in the maintenance of a healthy 
pregnancy. The members of the system are expressed throughout gestation in decidua, 
placenta and myometrium [372, 390-394]. Moreover, the major endocannabinoid AEA is 
present in human female reproductive tissues, namely in placenta, foetal membranes and 
also in cord blood, umbilical vein and artery [395]. During the first and second trimesters 
of human pregnancy, the plasma levels of AEA are comparable to those registered in the 
luteal phase of menstrual cycle, slightly increasing in third trimester, which is in agreement 
with the required low levels of AEA in the early stages of pregnancy [351, 361].   
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Decidua is the maternal tissue that supports the embryo growth and maintains the early 
pregnancy by protecting the embryo from maternal immune system and participates in 
gas and nutrients exchanges. In women, decidualization is independent of blastocyst’s 
presence, since it occurs in every luteal phase of menstrual cycle to prepare the uterus for 
an eventual pregnancy. The formation of decidua and placenta is a highly regulated 
process that involves a network of hormones and cytokines, where eCBs also seem to 
play an important role. In fact, the CB1 receptor agonist WIN inhibits human 
decidualization and induces apoptosis by decreasing cAMP levels, a second messenger 
that enhances decidualization [396]. Moreover, in primary cultures of rat decidual cells, 
AEA and 2-AG induce apoptosis by CB1 activation, suggesting a role for ECS in rat 
decidual regression [138, 175].  
The study of CB receptors expression in rat foetoplacental units revealed that CB1 
expression is more intense than CB2 and is highest with the maximum decidual 
development [397]. The levels of AEA and 2-AG in plasma and decidual tissue fluctuate, 
though plasmatic levels do not correlate with tissue levels, suggesting an in situ enzymatic 
regulation of eCBs levels [175, 398]. Moreover, NAPE-PLD and FAAH activities in 
maternal tissues increase throughout pregnancy and the NAPE-PLD:FAAH ratio is higher 
when the decidua reaches its maximal development [399].  
In the human placenta, CB receptors expression was described for the first time by 
Kenney et al. in term placentas and in the choriocarcinoma cell line BeWo [400]. Park et 
al. reported that, in term placenta, CB1 was expressed in all tissues while FAAH 
expression was more diffuse, with highest expression in the decidua and amnion; the ST 
presents higher FAAH expression than CTs [392]. In first trimester placenta, Heliwell et al. 
observed that FAAH was expressed in EVTs, CTs and ST. Moreover, its expression 
seems to be modulated during gestation since its mRNA peaks at the week 11, then 
decreasing till the end of pregnancy [401]. Recently, Habayeb et al. analysed the 
temporal-spatial expression of FAAH and CB receptors during early pregnancy and 
demonstrated that, besides FAAH, both CB1 and CB2 are also expressed in placenta. In 
fact, CB1 receptor was expressed in CTs and ST but, in the latter, the signal intensity 
diminished at 10th week. CB2 receptor expression remained constant during early 
pregnancy [139]. Moreover, FAAH was also expressed throughout placental tissues but 
the signal in ST increased gradually, peaking at 10th week of gestation, decreasing 
thereafter [139]. These data support a role for FAAH in the regulation of placental AEA 
levels and indicates that this enzyme may play a role in foetal protection against maternal 
blood AEA, in the initial stages of pregnancy. A recent study demonstrated that, in 
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preeclamptic placentas, NAPE-PLD was upregulated whereas FAAH was downregulated, 
in comparison with normal placentas [402], suggesting that deregulations of the ECS may 
be implicated in the pathophysiological mechanisms of preeclampsia.  
In women that underwent spontaneous abortion, high levels of CB1 receptor and very 
low levels of FAAH were found in 1st trimester placentas, comparatively with placentas of 
women that underwent voluntary pregnancy termination [403]. The AEA plasma levels of 
women with recurrent spontaneous miscarriages was about 3-fold higher than those 
observed in women with successful gestations [404]. Moreover, decreased FAAH levels 
were detected in lymphocytes of pregnant women that later suffered spontaneous 
miscarriage [405]. Also, FAAH levels in lymphocytes of women who failed to achieve an 
ongoing pregnancy after IVF-embryo transfer were lower comparatively with women that 
became pregnant, and as expected, blood levels of AEA were higher [406]. Due to these 
reports, low FAAH levels in peripheral lymphocytes have been proposed as an early 
marker of human spontaneous miscarriage.  
Sun et al. observed an inhibition of trophoblast stem cells proliferation, differentiation 
and invasiveness in CB1 knockout mice, causing an abnormal placentation, due to the 
decrease of  AKT phosphorylation [407]. Microarray data reported that silencing or 
enhancing CB1 signalling in these cells affected the expression of several genes, 
compromising cell migration [408]. Moreover, AEA inhibits the proliferation of BeWo cells 
through CB2 receptor [139] and THC decreases BeWo cells proliferation and modulates 
genes encoding for proteins involved in growth, apoptosis, cell morphology and ion 
channels [409].  
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Aims 
Placental formation and development requires tightly coordinated processes of 
trophoblast cells proliferation, apoptosis and differentiation. Although various molecules 
and signalling pathways have been identified as regulators of these processes, there are 
still pieces missing to fully understand the complexity of the placental development.  
The endocannabinoids have been pointed as new modulators in neuroprotection, 
apoptosis, pain modulation or inflammation. In the biology of reproduction, a role for the 
ECS has already been recognized in the processes of decidualization and implantation. 
Nevertheless, the linkage between these lipids and the human placental development has 
been poorly explored, though some ECS members (CB1, CB2, FAAH and NAPE-PLD) 
have already been described in placental tissues. In this way, one of the major aims of 
this work will be to search for the expression of other members, such as the main 2-AG 
metabolic enzymes (DAGL-α, MAGL) and of the AEA target, TRPV1, in primary human 
cytotrophoblasts, syncytiotrophoblast and in the cytotrophoblast cells BeWo, a widely 
used model of CTs. How the turnover of villous trophoblast is regulated is important for 
understanding normal and complicated pregnancies. In that way, the impact of 
endocannabinoids in the processes of cytotrophoblast apoptosis and differentiation and 
the underlying signalling pathways will be studied. The role of endocannabinoid and 
endovanniloid signalling during CTs biochemical and morphological differentiation into 
STs will also be explored by the analysis of the effects on the modulation of placental 
proteins expression such as hCG, leptin and fusogenic proteins 
Together, this work aims to shed light on the role of endocannabinoids in 
cytotrophoblast cell turnover, and the cellular mechanisms behind their effects. These 
studies may contribute to identify novel modulators of cytotrophoblast remodelling and, 
consequently, of placental development and also to unravel the involvement of 
deregulations of ECS in the pathophysiology of some pregnancy-related complications. 
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ABSTRACT 
Introduction: A balanced proliferation, apoptosis and differentiation in 
trophoblast cells of the human placenta is crucial for a proper placental 
development. Alteration in trophoblast apoptosis and differentiation are 
associated with gestational-related complications, such as preeclampsia, 
intrauterine growth restriction or miscarriages. The endocannabinoids (eCBs) 
have been recognized as new interveners in pregnancy events such as 
implantation and decidualization. However, their importance in placentation is 
poorly understood. We hypothesise that these novel lipid mediators may 
intervene in cytotrophoblast apoptosis and, concomitantly, have a role during 
placental development. 
Methods: primary human cytotrophoblasts (hCTs) and the human 
trophoblast-like choriocarcinoma cell line BeWo cells were exposed to 
Anandamide (AEA). It was investigated the cellular pathways involved in cell 
death, by the assessment of cell morphology, caspases activity, mitochondrial 
membrane potential (∆ψm), reactive oxygen/nitrogen species (ROS/RNS) and 
western blot of cleaved Poly (ADP-ribose) polymerase 1 (PARP-1), truncated 
Bid (t-Bid) and  IκB-α. 
 Results: AEA decreased hCTs viability and induced morphological features 
of apoptosis (chromatin condensation and fragmentation), caspase-3/7 activation 
and PARP-1 cleavage. In BeWo, AEA also increased the activities of caspase-
3/7 and 9, induced loss in ∆ψm and production of ROS/RNS. These effects were 
reversed by either CB1 or CB2 antagonists, whereas the increase in caspase 3/7 
activity was only reversed with CB2 blockage. AEA-treated cells showed 
increased caspase-8 activation and formation of t-Bid, suggesting the interplay 
between intrinsic and extrinsic apoptotic pathways. AEA also increased IκB-α 
expression, a NF-κB regulatory protein.  
Conclusion: Our results highlight the importance of eCBs in cytotrophoblast 
cell apoptosis and indicate that a crosstalk between intrinsic and extrinsic 
apoptotic pathways is involved in AEA-induced effects. 
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1. Introduction 
 
The placenta is a specialized organ with vital 
functions, such as nutrient and gas exchange, 
immunomodulation and protein biosynthesis. 
The main placental cells, the trophoblasts, are 
subdivided in different cell types: 
cytotrophoblasts, syncytiotrophoblast and 
extravillous trophoblasts (EVTs). 
Cytotrophoblasts are mononuclear cells that 
proliferate, fuse and differentiate into other types 
of trophoblasts. The syncytiotrophoblast is a 
multinucleated layer that produces several 
hormones and proteins and is in direct contact 
with maternal blood, allowing the mother-foetus 
communication. The EVTs have invasive 
properties and are involved in the uterine blood 
vessels remodelling [1]. A coordinated 
proliferation, differentiation and apoptosis of 
trophoblasts is required for a proper placental 
development, and any disturbance in these 
processes is associated with gestational 
complications [2-7]. 
The Endocannabinoid System (ECS) has 
emerged as a key modulator of multiple 
physiological and pathophysiological processes, 
including reproductive events like implantation 
and decidualization. This system comprises the 
two cannabinoid receptors CB1 and CB2, their 
endogenous ligands (endocannabinoids- eCBs), 
the enzymes involved in eCBs biosynthesis and 
degradation and a putative membrane transporter 
(See [8] for review). Anandamide (AEA) or N-
arachidonoylethanolamine was identified in 
1992 in pig brain [9] and is currently the best 
studied eCB. It is synthesised from membrane 
phospholipids in a two-step reaction catalysed by 
the enzymes N-acyltransacylase and N-
acylphosphatidylethanolamine-phospholipase D 
(NAPE-PLD). After exerting its effect, it is 
hydrolysed inside the cell, mainly by Fatty Acid 
Amide Hydrolase (FAAH), an inner cellular 
membrane enzyme. This eCB induces apoptosis 
in several cell types by activating different 
receptors and cell signalling pathways. In fact, it 
was described that AEA-induced apoptosis 
involve the activation of its main targets, the CB 
receptors, triggering several downstream 
pathways, including activation of mitogen-
activated protein kinases (MAPKs), increase of 
ceramide levels or intracellular Ca2+ and 
generation of oxidative stress  [10-14]. 
The importance of cannabinoid signalling 
homeostasis was only been recently recognized. 
In fact, a proper AEA tone is required for 
embryo transport along the mouse oviduct [15] 
and low levels of this eCB are required in 
implantation sites and are mainly regulated 
locally by the enzyme FAAH (see [16] for 
review). Nevertheless, information about the role 
of AEA during the period of placental 
development is lacking. It was reported that CB 
receptors and AEA main metabolic enzymes are 
expressed in first trimester and term placentas 
[17-20]. Also, in preeclamptic placentas, NAPE-
PLD expression was increased whereas FAAH 
was decreased in comparison to normal 
placentas, suggesting a function for eCBs in the 
pathophysiology of preeclampsia [21]. It was 
also described that AEA decreases the viability 
of BeWo cells, via CB2 receptor [20].  
Moreover, we have recently demonstrated that 
the other major eCB, 2-arachidonoylglycerol (2-
AG), has the ability to induce apoptosis in BeWo 
cells through a CB receptor- and mitochondrial-
dependent mechanism [22].   
Here, we investigate the impact of AEA on 
cytotrophoblasts viability and explore the 
cellular mechanisms triggered by this 
endocannabinoid. We hypothesise that this major 
endocannabinoid may integrate the network of 
hormones, cytokines and other molecules that 
regulate cytotrophoblast proliferation and 
apoptosis. 
 
 
 
2. Materials and Methods 
 
All chemicals were from Sigma-Aldrich Co. 
(St. Louis, MO, USA), except: Anandamide, 
AM251 and AM630 (Tocris Bioscience, Bristol, 
UK); 3, 3′-dihexyloxacarbocyanine iodide 
(DiOC6) (Gibco/Invitrogen Corporation, 
Carlsbad, CA, USA); Z-VAD-fmk (BD 
PharMingen, San Diego, CA); CytoTox 96 
nonradioactive cytotoxicity assay kit, Caspase-
Glo® (Promega, Madison, WI, USA); 3H-
thymidine (Amersham, Aylesbury, UK); percoll 
(GE Healthcare, Buckinghamshire, UK); and 
WesternBrightTM ECL HRP substrate (Advansta, 
Menlo Park, USA). 
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2.1 Isolation and culture of human 
cytotrophoblasts 
All the procedures were performed in 
accordance with the Ethical Committee of 
Hospital S. João, Porto (authorization nº 237-
13). For each assay, cytotrophoblasts were 
isolated from five different term placentas from 
clinically normal pregnancies, according to a 
modification of the Kliman’s protocol, as 
previously described [23]. Briefly, decidual 
tissue was removed, villous tissue was collected 
from at least 10 different regions homogeneously 
distributed in the whole placenta, and the major 
blood vessels were discarded by fine dissection. 
Then, the tissue was digested in a trypsin and 
DNAse-containing solution and the obtained 
cells were separated in a discontinuous percoll 
gradient, at 1200 g. The cytotrophoblasts were 
collected and incubated at 37 °C and 95% air/ 
5% CO2 humidified atmosphere, in DMEM/F12 
medium supplemented with 10% (v/v) FBS and 
antibiotic–antimycotic solution (100 U/ml 
penicillin G, 100 μg/ml streptomycin, 0.25 μg/ml 
amphotericine B). To evaluate the purity of the 
cytotrophoblast cultures, cells were fixed with a 
4% paraformaldehyde solution and 
immunostained with anti-cytokeratin-7 and anti-
vimentin antibodies. Around 95% of the cells 
were cytokeratin-7 positive, which corresponds 
to the epithelial hCT cells. For the experiments, 
cells were plated in 6- and 96-well plates or 8-
well chamber slides, at densities 4.5 x 105, 1.5 x 
105 or 5 x 105 cells/well, respectively. 
 
2.2 BeWo cell culture conditions 
The human choriocarcinoma cell line BeWo 
(ATCC, Manassas, VA, USA) was incubated at 
37 °C and 95% air/ 5% CO2 humidified 
atmosphere, in DMEM/F12 medium 
supplemented with 10% (v/v) FBS and an 
antibiotic–antimycotic solution. For the 
experiments, cells were used between 78 and 90 
passages and seeded in 96 or 6-well plates and 8-
well chamber slides, at densities 1 x 104, 2 x 105 
and 3 x 104 cells/well, respectively. At least five 
independent experiments performed in triplicate 
for each assay. 
For the investigation of cellular pathways 
triggered by AEA, BeWo cells were pre-treated 
for 30 min with CB1 and CB2 antagonists, 
AM251 or AM630 (1 μM), respectively. AEA, 
AM251 and AM630 were dissolved in ethanol. 
Equimolar concentrations of the vehicle did not 
induce any effects on all the parameters (data not 
shown). 
2.3 Cell viability and cytotoxicity assays 
The hCTs and BeWo cells were plated in 96-
well plates and, after adhesion, incubated in 
DMEM/F12 medium with 1% FBS and 1% 
antibiotic solution, in the absence or presence of 
AEA (1-25 µM) for 12 and 24 h (hCTs) or for 
24, 48 and 72 h (BeWo cells). The yellow 
tetrazole MTT (0.5 mg/ml final concentration) 
was added and cells were incubated for 2 h 30 
min, at 37 ºC. The resultant purple formazan was 
extracted by a solution Dimethylsulfoxide 
(DMSO):isopropanol (3:1) and quantified by 
spectrophotometry, at 540 nm, in a Multiscan 
Ascent microplate reader. The activity of the 
cytoplasmic enzyme lactate dehydrogenase 
(LDH) released into the culture medium was 
assessed by the CytoTox 96 nonradioactive 
cytotoxicity assay kit, according to the 
manufacturer’s instructions.  
 
2.4  Morphological studies 
The alterations in cell morphology induced 
by AEA (15 μM) treatment of hCTs for 24 h or 
AEA (10 μM) treatment of BeWo for 48 h were 
analysed by Giemsa and Höechst staining. These 
concentrations were selected according to the 
viability assays of each cellular model.  After the 
treatment, cells plated in 8-well chamber slides 
were fixed with a 4% paraformaldehyde 
solution, stained with Giemsa and analysed 
under light microscopy. For Höechst staining, 
cells were exposed to 0. 5 mg/ml Höechst 33342 
for 20 min and examined under a fluorescence 
microscope (Eclipse E400, Nikon, Japan) 
equipped with an excitation filter with maximum 
transmission at 360/40 nm.  
 
2.5 Incorporation of 3H-thymidine 
The impact of AEA in BeWo cells 
proliferation was evaluated by the quantification 
of 3H-thymidine incorporation in the absence or 
presence of AEA (1-25 µM) for 24 and 48 h. 3H-
thymidine (0.5 μCi final concentration) was 
added to each well, 8 h before the end of the 
incubation time. Cells were frozen/thawed twice, 
harvested with a semi-automated cell harvester 
(Skatron Instruments, Lier, Norway). After the 
addition of scintillation cocktail, the 
incorporation of 3H-thymidine was quantified in 
a scintillation counter (LS 6500, Beckman 
Instruments, Fullerton, CA, USA). 
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2.6 Determination of Caspase-3/7, 8 and 9 
activities 
The activity of caspases was determined by 
luminescence assays by using caspase-Glo®-3/7, 
8 or 9 assays, according to manufacture 
instructions. Cells were seeded in 96-well white 
plates and exposed to 15 μM of AEA for 20 h (in 
case of hCTs) or to 10 μM of AEA for 36 h (in 
case of BeWo cells). The plates were incubated 
for 1 h at room temperature and the resultant 
luminescence was measured in a Microplate 
Luminometer (BioTek Instruments, Winooski, 
VT, USA) and presented as in relative light units 
(RLU). A negative control was performed by co-
incubation of AEA with a specific caspase 
inhibitor, Z-VAD-fmk (20 μM) and a positive 
control was performed with the apoptosis 
inductor staurosporine (STS; 100 nM) added 12 
h before the end of experiment.  
 
2.7 Evaluation of mitochondrial membrane 
potential (∆ψm) and intracellular reactive 
oxygen and nitrogen species (ROS/RNS) 
For the assessment of ∆ψm and ROS/RNS 
production, BeWo cells were seeded in 96-well 
black plates and treated with AEA (10 μM) for 
36 h or 48 h, respectively. For ∆ψm studies, cells 
were washed and incubated with DiOC6 100 nM, 
for 20 min, at 37 ºC, in the dark. For the 
evaluation of ROS/RNS production, cells were 
washed and incubated with the fluorescent probe 
2,7-Dichlorodihydrofluorescein diacetate 
(DCDHF-DA), for 1 h, at room temperature. For 
both assays, the resulting fluorescence was 
measured in a Microplate Fluorimeter (BioTek 
Instruments, Vermont, USA) (excitation-485+/-
10 nm; emission 530+/-12, 5 nm). The positive 
controls for ∆ψm or ROS/RNS production were 
the mitochondrial depolarizing carbonyl cyanide 
m-chlorophenylhydrazone (CCCP; 10 μM) or 
H2O2 (200 μM), respectively. The results were 
expressed in relative fluorescence units (RFU). 
 
2.8  Western Blot analysis 
Western Blot was used for the assessment of 
cleaved PARP-1 in hCTs and Bid/t-Bid and IκB-
α (Table 1). BeWo cells were seeded in 6 well 
plates and incubated in the absence or presence 
of AEA alone or pre-incubated with CB 
receptors antagonists. After 24 or 48 h, for hCTs 
and BeWo respectively, cells were lysed in ice-
cold lysis buffer (20 mM Tris, 100 mM NaCl, 1 
mM EDTA, 1% TritonTM X-100). Proteins were 
resolved in SDS-polyacrylamide gel 
 
 
 
Table 1. Summary of the electrophoresis conditions. All the antibodies were from Santa Cruz 
Biotechnology (Dallas, Texas, USA), except anti-Bid, which was from Cell Signaling Technology 
(ZA Leiden, Netherlands) 
 
Protein 
Molecular 
Weight 
(kDa) 
SDS‐PAGE 
(%) 
Positive 
control 
Primary antibody Secondary antibody
source dilution source  dilution
IκB‐α  35  10 %  Hela cells extract  Rabbit  1:400  Goat anti‐rabbit  1:2000 
Cleaved 
PARP‐1  85  10 % 
BeWo cells 
treated 
with STS 
Rabbit  1:100  Goat anti‐rabbit  1:1000 
BID/t‐BID  22/15  15 %  Hela cells extract  Rabbit  1:200  Goat anti‐rabbit  1:1000 
β‐tubulin  55      Rabbit  1:750  Goat anti‐rabbit  1:3000 
 
 
 
 
electrophoresis (SDS-PAGE) and transferred 
onto nitrocellulose membranes. After blocking 
nonspecific binding sites, membranes were 
incubated with the corresponding primary 
antibody, overnight, at 4 ºC, and then with 
peroxidase-conjugated secondary antibody for 1 
h, at room temperature. Lastly, a Western 
BrightTM ECL was added to the membranes and 
exposed to x-ray film. Membranes were then 
stripped and reincubated with anti-tubulin 
antibody for loading control. The signal intensity 
was quantified by densitometry (BIO-PROFIL 
Bio-1D2; Vilber Lourmat, Marne-la-Vallée, 
France) and the results expressed in arbitrary 
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units, after normalization for the corresponding 
β-tubulin band.  
 
 
2.9 Statistical analysis   
Statistical analysis was carried out by 
Wilcoxon signed-rank, Mann-Whitney or 
Kruskal-Wallis tests followed by multiple 
comparisons with Dunn’s test (GraphPad PRISM 
v. 6.0, GraphPad Software, Inc., San Diego, CA, 
USA). The results are the mean of at least five 
independent experiments performed in triplicate. 
Data were expressed as mean ± SEM and 
differences were considered to be statistically 
significant at p<0.05. 
 
3. Results 
 
3.1 AEA effects in primary cultures of human 
cytotrophoblasts 
Treatment of hCTs with AEA decreased cell 
viability, in a concentration dependent manner, 
for concentrations higher than 15 μM (Figure 
1A). Similar effects were observed at 12 and 24 
h of treatment. LDH release was also evaluated 
to study the cytotoxic effects of AEA. Only the 
highest concentration (25 μM) induced a 
significantly release of this enzyme (Figure 1B).  
The impact of AEA in hCTs morphology was 
investigated by Giemsa and Höechst staining. 
Cells treated with AEA (15 μM) showed 
chromatin condensation and fragmentation 
(Figures 1C-F).  In addition, it was observed an 
increase of 28% in caspase-3/7 activity, after 20 
h of treatment (Figure 1G) and an increase in 
PARP-1 cleavage (Figure 1H).   
 
3.2 AEA effects in cell viability and 
proliferation of BeWo cells 
The human cytotrophoblasts spontaneously 
differentiate in vitro into syncytiotrophoblasts, 
after 72 h of culture [24], hampering the study of 
the cytotrophoblast cell population in primary 
cultures. Thus, BeWo cells were chosen as a 
model to carry out the investigation of the 
cellular pathways triggered by AEA. These cells 
are widely used as a representative model of 
hCTs since they are able to proliferate and do not 
significantly differentiate without a stimuli, to 
allow the study of AEA effects on 
cytotrophoblast viability. Additionally, they 
express CB receptors and other members of ECS 
and respond to cannabinoid stimuli [20, 22]. The 
exposure of BeWo cells to AEA diminished cell 
viability, in a concentration and time dependent 
manner (Figure 2A). In fact, a 24 h treatment 
with 15 μM AEA significantly decreased cell 
viability by 26%. After a 48 h treatment, a cell 
viability loss was observed with 10 μM AEA 
(about 20%) and a dramatic reduction on cell 
viability was observed with 25 μM (by 74%). At 
72 h of treatment, lower concentrations of AEA 
(5 μM) affected cell viability and 10 μM induced 
a massive cell death (around 55%). LDH release 
was assessed in order to evaluate the 
involvement of a cytotoxic mechanism in AEA 
effects on cell viability (Figure 2B).  Higher 
concentrations than 25 or 15 μM significantly 
increased LDH release, after 24/48 h or 72 h of 
treatment, respectively. The 3H-thymidine 
incorporation assay showed that BeWo cells 
proliferation was also decreased by 23% with 15 
or 10 μM AEA, after a 24 or 48 h exposure, 
respectively (Figure 2C). This effect was more 
notorious with higher concentrations of AEA. 
In the following experiments that aim to 
study the cellular pathways involved in AEA-
induced cell death, BeWo cells were treated with 
10 μM of AEA for 48 h, since in these 
conditions AEA decreased cell viability and 
proliferation without inducing LDH release. To 
clarify the involvement of CB receptors in the 
cellular mechanisms behind the AEA-induced 
decrease in BeWo cells viability, cells were pre-
treated with selective antagonists of CB1 and 
CB2, AM251 and AM630, respectively, which 
per se did not interfere with cell viability (Figure 
2D). 
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Figure 1. Anandamide (AEA) effects in
human cytotrophoblast cells (hCTs). (A)
MTT assay showed that AEA decreased
hCTs viability after 12 and 24 h of
treatment, in a concentration-dependent
way, for concentrations higher than 15
μM and (B) LDH release was only
significantly increased for 25 μM.
Giemsa staining revealed that the 24 h-
treatment with 15 μM of AEA induced
chromatin condensation (arrows) (E), in
comparison to the control (C). Höechst
staining confirmed the presence of nuclei
with chromatin condensation (arrows) in
AEA-treated hCTs (F), in comparison
with the control (D). (G) Caspase 3/7
activity was increased in cells treated
with AEA for 20 h and (H) there is an
increase of PARP-1 cleavage after a 24 h
treatment; STS was used as positive
control. (*p < 0.05 vs. Control;
Wilcoxon signed-rank test for A and B;
Mann-Whitney for G and H). LDH-
Lactate dehydrogenase; MTT-
Methylthiazolyldiphenyl-tetrazolium 
bromide; STS- Staurosporine. 
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Figure 2. Anandamide (AEA)
effects in BeWo cells viability and
proliferation, after 24, 48 or 72 h
of exposure. (A) MTT assay
revealed a decrease in cell
viability, in a concentration and
time -dependent manner (for
concentrations higher than 5 μM).
(B) LDH release was significantly
increased for concentrations
higher than 20 μM, for 24 and 48
h treatments; and then 15 μM, for
72 h treatment. (C) The
incorporation of 3H-thymidine
was decrease for 10 μM or higher
concentrations of AEA. (D) CB
receptors antagonists, AM251 and
AM630 (1 μM), did not interfere
with cell viability, after a 48 h-
treatment. (*p < 0.05 vs. Control;
Wilcoxon signed-rank test). MTT-
Methylthiazolyldiphenyl-
tetrazolium bromide; LDH-
Lactate dehydrogenase. 
 
     
 
3.3 AEA effects in BeWo cells morphology  
The morphological alterations induced by 
AEA in BeWo cells were observed by Giemsa 
and Höechst staining. AEA-treated cells (10 μM) 
presented morphological features that are 
characteristic of apoptosis like chromatin 
condensation and fragmentation and the presence 
of apoptotic bodies (Figure 3).  
 
 
3.4 Study of the mechanisms of cell death 
triggered by AEA in BeWo cells 
As morphological studies indicated the 
presence of apoptotic features, we evaluated 
AEA effects on the activity of the effector 
caspases-3/7 and also the involvement of 
intrinsic pathway, by the assessment of caspase 9 
activity and mitochondrial membrane potential 
(∆ψm). We found that this eCB induced a 16% 
increase in caspases-3/7 activity, effect that was 
partially reversed by the CB2 antagonist (Figure 
4A).  Moreover, AEA caused an increment of 
24% of caspase-9 activity (Figure 4B) and a loss 
of 16% of mitochondrial membrane potential 
and the effects were partially reversed by both 
CB receptors antagonists, AM251 and AM630 
(Figure 4C). The effects of AEA in the 
production of ROS/RNS were also evaluated, 
using the probe DCDHF-DA. AEA dramatically 
exacerbated the generation of ROS/RNS, in 
comparison with control. Both CB receptors 
antagonists were able to partially reverse this 
effect (Figure 4D).  
To explore if the extrinsic pathway was 
triggered by AEA in BeWo cells, we 
investigated the effects of this eCB in proteins 
related to the extrinsic pathway, caspase-8 
activity and t-Bid, and also in IκB-α, a regulatory 
protein that inhibits the NF-κB transcription 
factor. It was detected an increase of 19% in the 
activity of caspase-8, through a mechanism 
involving both CB1 and CB2 receptors (Figure 
5A) and an increase in the formation of t-Bid 
(Figure 5B). Moreover, AEA also increased the 
expression of IκB-α, suggesting that NF- κB is 
not activated (Figure 5C).  AEA effects on t-Bid 
and IκB-α were attenuated by CB1 and CB2 
antagonists, though without statistical 
significance.  
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Figure 3. Morphological analysis of BeWo
cells treated with anandamide (AEA) for 48
h.  In Giemsa staining, cells treated with
AEA (10 μM) presented cell shrinkage and
chromatin condensation (arrows) (C)
compared to untreated cells (A). Höechst
assay also revealed cells with chromatin
condensation (arrows) and the presence of
apoptotic bodies (arrow head) in AEA-
treated cells (D), in comparison with the
control (B). 
 
4. Discussion 
The endocannabinoid signalling participates 
in the modulation of several physiological and 
pathophysiological events in different tissues and 
organs. AEA has been pointed out as a player in 
gestational events like implantation [25] and 
decidualization [26], where it induces apoptosis 
through CB1 receptor activation. However, the 
role of AEA in placental development is not 
completely understood. In this work, we report 
that AEA causes a decrease in cell viability of 
primary human cytotrophoblasts accompanied 
by apoptotic morphological features and 
biochemical markers such as caspase-3/7 
activation and cleavage of PARP-1. Human 
cytotrophoblasts spontaneously differentiate in 
vitro into syncytiotrophoblasts, impairing the 
study of the cytotrophoblast cell population. 
Therefore, we chose to study AEA effects on the 
cytotrophoblast cell model, BeWo cells, and 
concluded that this eCB affected cell viability, 
results that were in agreement to those already 
described [20].  
The antagonist of CB2 receptor was also able 
to reverse AEA-induced increase in caspase 
activities, loss of ∆ψm and ROS/RNS 
generation. However, CB1 receptor is also 
involved in these effects since its antagonist 
attenuated all of them, with exception of the 
augment in caspase-3/7 activity. We previously 
reported that CB2 antagonist was also able to 
prevent the increase in caspase-3/7 and 9 
activities and viability loss induced by the other 
major endocannabinoid, 2-AG, supporting the 
importance of this receptor in eCB-induced 
apoptosis in BeWo cells [22]. Our data revealed 
that the intrinsic apoptotic pathway is activated 
in the AEA-induced apoptosis, as supported by 
the loss of ∆ψm and the increase in caspase-9 
activity. The involvement of the intrinsic 
pathway in the apoptotic effects of AEA has 
been described in several cell types. In fact, we 
have previously reported that AEA induces 
apoptosis in rat decidual cells, through a CB1-
dependent mechanism involving caspase-9 
activation, loss of ∆ψm, ceramide accumulation 
and phosphorylation of p38 [10]. Furthermore, in 
glioma cells, AEA also induced cytochrome c 
release via CB1, dependently on lipid rafts [27]. 
In pheochromocytoma PC12 cells, AEA induced 
cytochrome c release through the activation of 
p38 and JNK pathways [28]. 
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Figure 4. The influence of anandamide 
(AEA) in apoptotic markers and production 
of reactive species of oxygen and nitrogen 
(ROS/RNS) in BeWo cells. (A) After 36 h 
of treatment, AEA (10 μM) augmented the 
activity of caspases 3/7 and this effect was 
partially reversed by the CB2 antagonist 
AM630. (B) In comparison with untreated 
cells, AEA induced an increase in caspase 9 
activity and both CB receptors antagonists 
partially reversed this effect. (C) AEA 
induced mitochondrial membrane potential 
(∆ψm) loss, effect reversed by both CB1 
and CB2 antagonists; CCCP, a depolarizing 
gent was used as a positive control. (D) 
AEA dramatically incremented the 
ROS/RNS production, after a 48h treatment 
and this effect was significantly reversed by 
both CB receptors antagonists. (*p < 0.05 
vs. Control; #p < 0.05 vs. AEA 10 μM; 
Kruskal-Wallis test followed by Dunn’s 
multiple comparison test). DiOC6- 3, 3′-
dihexyloxacarbocyanine iodide; CCCP-
carbonyl cyanide m-
chlorophenylhydrazone; DCDHF-DA- 2, 7-
Dichlorodihydrofluorescein diacetate; STS-
Staurosporine. 
  
 
AEA increased caspase-8 activity via a CB 
receptor-dependent mechanism. It is important to 
mention that caspase-8 is involved in non-
apoptotic cellular events such as proliferation, 
migration and differentiation [29]. This protease 
may be relevant for cytotrophoblast fusion and 
differentiation, though its role is not well 
established [30-32]. The activation of caspase-8 
implies a dimerization and autocleavage at 
DISC. The homodimerization leads to full 
activation of procaspase 8 initiating the apoptotic 
process. However, the heterodimerization of 
procaspase-8 with the regulatory protein FLICE 
inhibitory protein (FLIP) limits procaspase-8 
autoprocessing, allowing the initiation of a 
nonapoptotic pathways, mainly by the activation 
of the transcription factor NF-κB [29, 33]. Thus, 
caspase-8 may be an important molecule in the 
cell fate decisions between death and survival. 
Our results showed that NF-κB inhibitor protein, 
IκB-α, was upregulated in AEA-treated BeWo 
cells, indicating that the NF-κB pathway was not 
active and confirming the role of caspase-8 in 
the apoptotic process. In addition, we detected an 
increased formation of t-Bid. The cleavage of 
Bid by caspase-8 gives rise to t-Bid [34]. In this 
way, our data suggest that there is a crosstalk 
between the extrinsic and intrinsic apoptotic 
pathways, in AEA-induced apoptosis in BeWo 
cells. Other authors have already reported that 
AEA triggers the extrinsic apoptotic pathway. In 
fact, in cholangiocarcinoma cells, AEA caused 
apoptosis through a CB receptor-independent 
mechanism, by accumulation of ceramide and 
recruitment of Fas and FasL into lipid rafts [35]. 
More recently, these effects were attributed to 
the activation of GPR55 [36]. In Chang liver 
cells, AEA mediated cell death by activation of 
both extrinsic and intrinsic pathways, with 
upregulation of FasL, Bim and Bax, in a 
mechanism that also involved ceramide 
production, oxidative stress generation and 
phosphorylation of JNK and p38 [13].  
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Figure 5. Impact of anandamide (AEA) in caspase-8 activity, cleavage of Bid and IκB-α expression in BeWo cells treated 
with 10 μM. (A) After 36 h, AEA increased caspase 8 activity, effect that was partially reversed by CB1 and CB2 
antagonists. (B) After a 48 h treatment, AEA induced an increase of t-Bid formation and (C) increased the expression of the 
NF-κB regulatory protein, IκB-α, effects that were  attenuated by both CB receptor antagonists. β-tubulin was used as 
loading control. BeWo cells treated with staurosporine (Bid/t-Bid) and HeLa cells extract (IκB-α) were used as positive 
controls (PC). (*p < 0.05 vs. Control; #p < 0.05 vs. AEA 10μM; Kruskal-Wallis test followed by Dunn’s multiple 
comparison test). 
 
 
It was previously demonstrated that both 
mitochondrial and death receptors pathways 
regulate the programmed cell death of 
trophoblasts [3, 37] and that caspases mediate 
apoptosis in villous cytotrophoblasts [38]. In 
addition, an abnormal expression of apoptotic 
proteins such as Bax, Bcl-2 or FasL in these cells 
is associated with pathological conditions like 
preeclampsia, HELLP syndrome, IUGR and 
hyperglycaemia [4-7, 39, 40]. Moreover, 
disturbances to pro-oxidant/antioxidant 
equilibrium during pregnancy may impair the 
biological function of proteins and lipids [41, 42] 
and are also associated with pregnancy 
complications like preeclampsia, intrauterine 
growth restriction (IUGR) and gestational 
diabetes  [43-45].  
In summary, this work showed that AEA 
induces apoptosis in human cytotrophoblasts and 
in a cytotrophoblast cell model, in the latter by 
triggering a CB receptor-dependent mechanism 
that involves both intrinsic and extrinsic 
apoptotic pathways. In this way, this work 
contributes to clarify the influence of AEA in 
cytotophoblast cells turnover and reinforces the 
relevance of a balanced endocannabinoid 
signalling for a successful placental 
development, since anomalies in apoptosis and 
oxidative stress have been associated with the 
aetiology of pregnancy-associated conditions 
like preeclampsia or IUGR.  
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In the last years, ECS research has unveiled new players in several physiological and 
pathophysiological processes, such as apoptosis, inflammation, neuromodulation or 
reproduction. Endocannabinoids have been described as important modulators in embryo 
transport and implantation, decidualization and labour [140, 141, 410]. Furthermore, an 
abnormal endocannabinoid signalling has been associated with an impairment of these 
reproductive events, and concomitantly, with disorders like infertility and miscarriages 
[410]. A proper placental development is crucial for the success of pregnancy and 
involves a balanced proliferation, differentiation and apoptosis of the main foeto-placental 
cells, the trophoblasts [85]. Since these cellular events are tightly regulated by a complex 
network of hormones, cytokines and other molecules, it was postulated that the eCBs 
might also have a role during placentation. Although information about eCBs function 
during placental development is lacking, the presence of AEA metabolic enzymes, NAPE-
PLD and FAAH, and CB receptors were already described in human placenta [139, 392, 
401]. It was also reported that AEA decreases BeWo cells viability, through a CB2 
receptor-dependent mechanism [139]. In contrast, the effects and role of the other major 
endocannabinoid 2-AG in reproductive events have been less explored, especially during 
placentation. 
In this study, 2-AG main biosynthetic and hydrolysing enzymes, DAGL-α and MAGL, 
respectively, were found to be expressed in primary human cytotrophoblasts and 
syncytiotrophoblasts and in the cytotrophoblast cell model BeWo cells. The expression of 
the cation channel TRPV1, an AEA receptor, was also demonstrated. There was no 
differences between CTs and STs in DAGL-α, MAGL and TRPV1 mRNA levels and 
protein expression, suggesting that the expression is not depend on cell differentiation 
stage. Thus, the human trophoblasts are provided with the enzymatic machinery required 
to regulate the in situ levels of both major eCBs, AEA and 2-AG, indicating that these lipid 
mediators may have a role in placentation. Moreover, TRPV1 expression in trophoblasts 
raises questions about the role of the endovanniloid signalling during placental 
development. Although this receptor was initially described in neuronal cells and identified 
as a modulator of nociception or temperature sensing [205], it is now known that TRPV1 is 
expressed in several other cell types and participates in other biological processes, such 
as apoptosis, muscle contraction or inflammation [211, 212, 221]. Furthermore, TRPV1 
was identified in rat placenta, though its function remains unclear [394, 411]. After a 
deeper knowledge of the presence of ECS members in placenta, the impact of AEA and 
2-AG in CT proliferation, apoptosis and differentiation into STs, as well as the involvement 
of CB and TRPV1 receptors in these cellular events, was evaluated. 
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The proliferation and apoptosis studies were mainly performed in BeWo cells, since 
primary human CTs do not proliferate in vitro and spontaneously differentiate into STs, 
hindering the study of the cytotrophoblast cell turnover [412]. In addition, as BeWo cells 
are a widely used model of CTs, proliferate and express the members of ECS, they were 
considered a suitable model to our studies. Both AEA and 2-AG decreased BeWo cell 
viability and proliferation, which is, in the case of AEA, in accordance to other study 
already described by Habayeb et al. [139]. Moreover, cells treated with eCBs present 
morphological alterations such as chromatin condensation and fragmentation and the 
presence of apoptotic bodies, which are typical characteristics of the apoptotic cell death. 
In addition, both eCBs induced an activation of caspases-3/7 and -9, a loss of 
mitochondrial membrane potential (∆ψm) and generated reactive species of oxygen and 
nitrogen (ROS/RNS). This suggests the involvement of the mitochondrial pathway, which 
was dependent on CB receptor. In fact, both CB receptor antagonists reversed AEA and 
2-AG effects on ∆ψm and ROS/RNS production, whereas caspase activities and 2-AG 
viability loss were only reversed by CB2 blockade. In this way, CB2 seems to be essential 
to the execution of the apoptotic process, though CB1 activation was also involved in the 
apoptotic events.  
The importance of the apoptotic process during the placental development is widely 
accepted, since it permits the continuous trophoblast cell turnover, by removing the 
quiescent cells and allowing the arising of new ones. It was recently reported that villous 
cytotrophoblasts undergo caspase-dependent apoptosis [86] and that both extrinsic and 
intrinsic apoptotic pathways participate in this cellular event [89].  
The role of eCB in cell apoptosis, namely by the activation of mitochondrial pathway, 
has been described in various cell types. Indeed, both AEA and 2-AG induce programmed 
cell death in rat decidual cells through the activation of CB1 [175, 297]. Furthermore, 2-AG 
induces apoptosis in hepatic stellate cells by a mechanism that involves mitochondrial 
ROS production [178], whilst AEA also activates this process in several tumour cell types, 
by causing cytochrome c release, MAPKs phosphorylation, ceramide accumulation or 
increase in the intracellular Ca2+ levels [192, 326, 327, 413]. AEA is also able to induce 
apoptosis in other non-tumour cells, like pancreatic β-cells or chondrocytes [154, 414]. 
In this work, it was also observed that AEA increased caspase-8 activity through the 
activation of CB receptors and the formation of truncated Bid (tBid), which suggests 
activation of the death receptor pathway. The participation of this apoptotic pathway in 
AEA-induced cell death has been described in other cell types. In fact, AEA induced 
apoptosis in cholangiocarcinoma cells, by accumulation of ceramide and recruitment of 
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Fas and FasL into lipid rafts, through the activation of GPR55 [331, 332]. In addition, AEA 
mediated cell death by activation of both extrinsic and intrinsic pathways in Chang liver 
cells [333] and chondrocytes [154]. However and contrary to the results reported in BeWo 
cells, these effects were independent on CB receptors, which indicates that the 
mechanisms involved in AEA-induced apoptosis may be cell specific.  
Caspase-8 participates in non-apoptotic cellular events like proliferation, migration and 
differentiation, which are mainly triggered by the activation of NF-κB [415]. On the other 
hand, some authors suggested that this protease may be involved in cytotrophoblast 
differentiation, though this point has raised some controversies [39, 77, 78]. In BeWo 
cells, we demonstrated that AEA treatment did not activate NF-κB, since the expression of 
IκB-α (NF-κB inhibitor protein) was upreregulated, supporting a role for caspase-8 in AEA-
induced apoptosis. In addition, AEA treatment increased the formation of truncated Bid 
(tBid), which results from Bid cleavage by caspase-8 [416]. Thus, these results suggest 
that AEA may mediate a crosstalk between the two apoptotic pathways in BeWo cells. 
Contrary to AEA, preliminary results indicate that 2-AG did not alter the activity of this 
protease in BeWo cells and that the pathways triggered in these cells by the two major 
eCBs may differ.  
To further study the effects of eCBs in cytotrophoblast cells death, the apoptotic 
process was also investigated in primary human CTs. It was verified that AEA induce 
apoptosis in these cells, as indicated by the presence of apoptotic morphological features, 
increase in caspase-3/7 activity, loss of ∆ψm, cleavage of poly (ADP-ribose) polymerase 1 
(PARP-1) and ROS/RNS generation. However, AEA-induced cell apoptosis in primary 
CTs was TRPV1-dependent, since its antagonists were able to reverse AEA effects on 
cell viability, caspase 3/7 activity, loss of ∆ψm and ROS/RNS production. Moreover, the 
best characterized TRPV1 agonist, CPS, induced similar effects to those observed after 
AEA treatment. Supporting these data, TRPV1 activation by CPS has been associated 
with programmed cell death, in other cell types. It was reported that CPS induces 
apoptotic-related events such as caspase activation, loss of ∆ψm, cytochrome c release, 
MAPK phosphorylation or ROS generation [337, 417-421]. In addition, TRPV1 mediates 
AEA-induced apoptosis in other cell types [153, 336, 337], suggesting a biological role for 
TRPV1 in cell apoptosis. In fact, and on the contrary of the exogenous CPS, AEA is an 
endogenous lipid ubiquitously present in several tissues and organs, including the human 
placenta [395], pointing to a role for the endovanilloid signalling in cytotrophoblast cells 
turnover. In this way, it is suggested that, besides the ECS, the TRPV1 may intervene in 
the regulation of CTs apoptosis and integrate the network of molecules that tightly control 
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this process to allow a successful placentation. It was also observed that both CPS and 
AEA increase intracellular Ca2+ levels, by a TRPV1-dependent way. TRPV1 is a non-
selective cation channel but it has preference for calcium ions, suggesting a role for this 
receptor in regulation of calcium homeostasis. Ca2+ ions are important mediators in cell 
proliferation, differentiation and apoptosis of various cell types, including cytotrophoblasts 
[422]. Furthermore, the relation between the CPS-induced increase in intracellular Ca2+ 
levels and apoptosis was already described [417, 421]. This information further supports a 
role for TRPV1 in cytotrophoblast cell apoptosis.  
As referred above, eCBs induced an increase in ROS/RNS production in 
cytotrophoblasts involving the activation of CB and TRPV1 receptors. Although gestation 
is a natural state of  oxidative and nitrative stress, threats to pro-oxidant/antioxidant 
equilibrium due to increased ROS/RNS or diminished antioxidant defences may 
negatively impact the biological function of proteins and lipids [423, 424]. Furthermore, 
alterations in the redox status of placenta have been associated with gestational 
complications [425-428]. In this way, it is plausible that anomalies on 
endocannabinoid/endovanilloid signalling may interfere with the balanced placental redox 
status and be implicated in a poor pregnancy outcome. 
In human CTs, AEA induced apoptosis through TRPV1 activation instead of CB 
receptors activation, as occurred in the case of the cytotrophoblastic BeWo cells. These 
different mechanisms triggered by AEA may be explained by two reasons. Firstly, BeWo 
cells are a choriocarcinoma cell line and, though they have been widely used and 
accepted as a cytotrophoblast cell model, they keep tumour cells properties. Secondly, 
there is still no consensus if this cell line is representative of cytotrophoblast of first or third 
trimester of pregnancy, which have distinctive properties, e. g. different hCG secretion 
levels, proliferative and invasive capacity [429, 430]. Since we assessed AEA effects on 
CTs from term placenta, it is possible that the different properties of BeWo cells may 
influence the receptors activated by AEA.  
In summary, the results of this study suggest that both eCBs may be novel interveners 
in the regulation of cytotrophoblast apoptosis, which enlighten a role for these molecules 
during placentation. In addition, deregulations in endocannabinoid/endovanniloid 
signalling may have a negative impact in placental development, since altered apoptotic 
rates and expression of apoptotic proteins have been associated with gestational 
diseases, such as preeclampsia, HELLP syndrome, IUGR and hyperglycaemia [79, 80, 
83, 84, 431-433].   
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Besides proliferation and apoptosis, the formation of syncytiotrophoblasts 
(syncytialization) is another critical event for placentation. The syncytialization consists in 
fusion and biochemical differentiation of the mononuclear CTs. The syncytiotrophoblast is 
in direct contact with the maternal blood, constituting the barrier between the mother and 
foetus, which is responsible for gas exchange, nutrient supply and production of 
hormones and other proteins that are crucial for the gestational success [6]. ST is the 
main trophoblast cell type that synthesises proteins such as hCG, leptin or ecto-pALP, 
which are considered biochemical markers of syncytialization. In this work, it was verified 
that 2-AG impaired the biochemical differentiation of primary human CTs into STs. Indeed, 
2-AG decreased the ecto-pALP activity, hCG secretion and the transcription of LEP, the 
gene encoding for leptin. Moreover, these effects were reversed by both CB1 and CB2 
antagonists, except for pALP activity, which was only reversed by CB2 blockade. In 
addition, CPS also impaired this process, as shown by the decrease in ecto-pALP activity 
and hCG secretion, effects reversed by TRPV1 antagonists. On the contrary to 2-AG and 
CPS, AEA did not affect hCG secretion, though it decreased pALP activity independently 
of TRPV1 activation. The different action of AEA in syncytialization may be explained by 
its agonist activity on other receptors besides TRPV1 and CB receptors, for example the 
PPAR-γ [163], which is also expressed in human CTs [43]. This AEA promiscuity may 
implicate the triggering of different signalling pathways, which may be mutually 
neutralized, masking AEA individual effect on each receptor. Further studies are required 
to fully understand the AEA role in syncytialization. 
hCG and leptin have well recognized pleotropic effects throughout pregnancy and are 
essential for a proper placental development. Since 2-AG impairs hCG secretion and LEP 
transcription by a CB receptor-dependent manner, it is suggested that, besides interfering 
with CTs biochemical differentiation into STs, a deregulated endocannabinoid signalling 
may also impair the processes regulated by these two hormones. Moreover, CPS affects 
hCG secretion through TRPV1 activation, indicating that TRPV1 signalling influences the 
secretion of this hormone. Although no linkage between hCG and eCBs has been 
reported so far, it is known that leptin activates FAAH promoter in human T lymphocytes 
[365] and leptin knock-out mice have higher uterine levels of AEA and 2-AG [368]. In this 
work, it was described that 2-AG interferes with LEP transcription, suggesting the 
existence of a mutual regulation between leptin and ECS. Since the ecto-enzyme pALP 
expression is mainly restricted to the ST, it is widely used as a biochemical marker of 
syncytialization. It has been associated with the transport of maternal IgG to the foetus 
and a decrease on pALP activity was noticed in cytotrophoblasts from IUGR placentas 
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[434, 435]. 2-AG and CPS-induced decrease of its activity supports the effects of these 
molecules on CT biochemical differentiation. 
The participation of CB receptors and TRPV1 in cell differentiation has already been 
described. Indeed, CB1 activation impairs myoblasts differentiation [176] and stimulates 
neural progenitor cells [436] and mice trophoblast stem cells differentiation [407]. In 
addition, TRPV1 inhibits the differentiation of immature dendritic cells [215] and, on the 
other hand, its activation is important for osteoblasts and osteoclasts differentiation [216] 
and for myofibroblasts formation from corneal fibroblasts [217]. This information further 
supports that CB and TRPV1 receptor-mediated signalling may also regulate this 
important cellular event in human CTs.  
The morphological CT differentiation consists in the fusion of the mononucleated CTs 
to form the syncytial layer. This process is enhanced by the fusogenic proteins syncytin-1 
and -2, whose transcription is regulated by the transcription factor GCM-1 [13-16]. In this 
study, it was demonstrated that 2-AG diminished the number of nuclei in syncytium and 
the transcription of genes encoding GCM-1 and syncytin-2, through a CB receptor-
dependent mechanism.  
The cAMP/PKA signalling pathway is considered one of the most relevant pathways 
that participate in syncytialization, by regulating the synthesis of several proteins. In fact, 
this pathway intervenes in hCG, leptin and pALP synthesis [50, 71, 96, 104, 437] and cell 
fusion [51, 72]. It was verified that 2-AG decreased cAMP levels, by a CB receptor-
dependent mechanism. Moreover, this effect was reversed by pertussis toxin, an inhibitor 
of Gi/0 protein subunits, suggesting an action on Gi/0 protein-coupled CB receptors. When 
activated, these receptors decrease AC activity, diminishing cAMP levels, leading to an 
inhibition of PKA phosphorylation [283]. Supporting these data, it was demonstrated that 
2-AG also decreased p-PKA, effect that was reversed by CB1 and CB2 antagonists. 
Hereupon, the negative impact that 2-AG has in CT differentiation may result from the 
decreased levels of cAMP and consequently of PKA phosphorylation, after the Gi/0 protein-
coupled CB receptors activation. 
The syncytialization is one of the most important events during placental development 
and anomalies with this event have been related to gestational complications like 
preeclampsia, IUGR or miscarriages [438-441]. The results of this work suggest that ECS 
and TRPV1 are new modulators of this process, interfering with the secretion of important 
pregnancy-related hormones. Thus, threats to ECS or TRPV1 homeostasis may be 
involved in the patophysiological mechanisms of these diseases, since 2-AG affects not 
only the biochemical but also the morphological differentiation of CTs into STs.   
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In conclusion, in this work, it was demonstrated for the first time that the major 
enzymes responsible for the synthesis and hydrolysis of 2-AG, DAGL-α and MAGL 
respectively, are expressed in human CTs and STs, allowing an in situ regulation of 2-AG 
placental levels. In addition, the cation channel TRPV1 was also identified in these cells. 
The major eCBs AEA and 2-AG induced apoptosis and oxidative/nitrative stress in the 
cytotrophoblast cell model BeWo cells, through the activation of CB receptors. In human 
CTs, AEA also induced apoptosis through TRPV1 activation. Furthermore, it was reported 
that 2-AG affects the spontaneous in vitro biochemical and morphological differentiation of 
CTs into STs, by a CB receptor-dependent way that may result from decreased cAMP 
levels and PKA phosphorylation. Moreover, contrary to AEA, the TRPV1 agonist CPS was 
also able to impair the biochemical differentiation. In this way, 2-AG seems to be the most 
relevant eCB in the modulation of syncytialization process.  
 Together, these results shed light on a role for the endocannabinoid system and 
TRPV1 in placental development, suggesting that endocannabinoids and endovanniloids 
are novel interveners in the network of hormones, proteins and other mediators that 
regulate cytotrophoblast cell proliferation, differentiation and apoptosis. They also indicate 
that unbalanced endocannabinoid and endovanniloid signalling may have negative 
consequences in cytotrophoblast cell turnover and, concomitantly, compromise normal 
placental development. However, there is much more to unveil about the ECS in the 
human placenta. Future studies may rely on the effects of eCBs on the endocrine function 
of ST and the invasive properties of EVTs, two topics where the knowledge about role of 
these lipid molecules is still inexistent.  
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